SCODiA Report by MLBI Lab

Single-Cell Landscape of Colorectal Carcinoma: Cellular Heterogeneity, Immune Evasion, and Novel Therapeutic Targets

This single-cell RNA sequencing analysis of colorectal carcinoma (CRC) reveals a highly complex and reprogrammed tumor microenvironment. Malignant Intestinal Epithelial cells are predominantly aneuploid and exhibit widespread activation of cell cycle pathways and oncogenic signaling, along with recurrent genomic amplifications of key oncogenes like EGFR and MYC. The immune landscape is characterized by increased immunosuppressive regulatory T cells (Tregs) and exhausted CD8+ T cells, alongside a shift in macrophage polarization towards pro-tumorigenic M2C/M2B subtypes. Cancer-associated fibroblasts (CAFs) show distinct activation markers, contributing to stromal remodeling. Extensive cell-cell interaction analysis highlights crucial communication pathways, including immune checkpoints, growth factor signaling, and integrin-mediated adhesion, offering multiple avenues for therapeutic intervention.

Contents

0. Dataset overview
1. UMAP Visualization of Cell Populations by Condition, Sample, Cell Type, and Ploidy in Colorectal Carcinoma
2. UMAP Visualization of Major Cell Type Scores and Ploidy Status
3. Marker Gene Expression Across Colon Cell Subsets
4. Copy Number Variation Analysis in Intestinal Epithelial Cells
5. UMAP Visualization of CNV Patterns across Cell Types, Ploidy, Condition, and Samples
6. Minor Cell Type Population Analysis in Colorectal Carcinoma
7. T cell and Innate Lymphoid Cell Subpopulation Analysis in Colorectal Carcinoma
8. Differential T Cell Subset Proportions in Colorectal Carcinoma
9. Macrophage Subset Population Analysis in Colorectal Carcinoma
10. Macrophage Subset Population Shifts in Colorectal Carcinoma
11. Intestinal Epithelial Cell Ploidy Distribution in Colorectal Carcinoma
12. Cell-Cell Interaction Analysis in Colorectal Carcinoma Microenvironment
13. Condition-Specific Cell-Cell Interaction Patterns in Colorectal Carcinoma
14. Cell-Cell Interaction Analysis in Colorectal Carcinoma: Immune Checkpoint and Cell Cycle Pathways
15. Intestinal Epithelial Cell Surfaceome Marker Expression in Colorectal Carcinoma
16. Macrophage Condition-Specific Surfaceome Markers in Colorectal Carcinoma
17. Fibroblast Condition-Specific Surfaceome Marker Analysis in Colorectal Carcinoma
18. T cell CD4+ Condition-Specific Surfaceome Markers in Colorectal Carcinoma
19. Differential Expression of Cell Cycle Genes in Colorectal Carcinoma Epithelial Cells
20. Gene Ontology (GSA) Analysis for Intestinal Epithelial Cells in Colorectal Carcinoma
21. Gene Set Enrichment Analysis (GSEA) of Cell-Type-Specific Pathways in Colorectal Carcinoma
22. Discussion
23. Query List

0. Dataset overview

Dataset Summary

• Dimensions: The AnnData object contains 85,038 cells and 27,779 genes.
• Species & Tissue: The data is from human samples, specifically colon tissue.
• Observed Conditions: The dataset includes two main conditions: 'Tumor' and 'Adj_normal'.
• Key Cell Type Annotations: Cells are categorized by celltype_major, celltype_minor, and celltype_subset, providing a granular hierarchy of cell types. Examples include 'Myeloid cell', 'Intestinal Epithelial cell', 'T cell', 'Macrophage', 'Enterocyte', and many more specific subsets.
• Ploidy Status: The dataset provides ploidy labels, with 85.7% of cells identified as Diploid and 14.1% as Aneuploid.
• Tumor Origin: 'Intestinal Epithelial cell' is identified as the resolved tumor-origin cell type, indicating its relevance to colorectal cancer.
• Genomic Information: CNV (Copy Number Variation) estimates are available, and var columns include chr, spot_no, and cytogenetic_band.
• Reference Condition: 'Adj_normal' is set as the reference condition for comparative analyses such as DEG, GSEA, and GSA.

Available Precomputed Results

The dataset is rich with precomputed analysis results:

• Cell-Cell Interactions (CCI): Results from CellPhoneDB are available per condition (uns['CCI']) and per sample (uns['CCI_sample']).
• Differential Gene Expression (DEG): Results are stored for each celltype_minor, comparing one condition against the rest (uns['DEG']).
• Gene Set Enrichment Analysis (GSEA): GSEA results are available per celltype_minor, comparing conditions (uns['GSEA']).
• Gene Ontology (GSA/GO): GO (GSA) results are provided for each celltype_minor, comparing conditions (uns['GSA_up']).

Inferred Biological Context: Colorectal Carcinoma

• The dataset's metadata, including 'Tumor' and 'Adj_normal' conditions in 'Colon' tissue, along with the presence of 'Aneuploid' cells and the 'Intestinal Epithelial cell' as the tumor-origin cell type, strongly suggests a focus on Colorectal Carcinoma. Cancer-specific metadata like 'HistologicTypeSimple', 'MMRStatus', and 'TumorStage' further support this context.

1. UMAP Visualization of Cell Populations by Condition, Sample, Cell Type, and Ploidy in Colorectal Carcinoma

[Analysis Visualization Results]...

Analysis Overview

This analysis presents Uniform Manifold Approximation and Projection (UMAP) plots, a powerful dimensionality reduction technique used to visualize high-dimensional single-cell RNA sequencing data in two dimensions. Each plot illustrates the distribution of cells, colored by different metadata attributes: experimental condition (Tumor vs. Adj_normal), individual sample origin, major cell type, minor cell type, cell subset, and ploidy status (Aneuploid, Diploid, Unclear). These visualizations are crucial for assessing the overall structure of the dataset, evaluating the quality of cell annotations, identifying batch effects, and observing major biological distinctions between conditions and cell states in the context of colorectal carcinoma.

Visual Summary

Condition UMAP

• The UMAP colored by condition shows a notable separation between cells from 'Tumor' and 'Adj_normal' conditions. While there is some intermingling, distinct regions are predominantly occupied by either tumor-associated or adjacent-normal cells. This suggests significant gene expression differences driven by the disease state.
• Specifically, certain large clusters appear to be enriched for 'Tumor' cells (e.g., the large cluster in the lower right and some smaller ones on the upper right), while others are primarily 'Adj_normal' (e.g., a large central cluster and parts of the left-most clusters). This segregation indicates a robust biological signal related to the tumor microenvironment and cellular changes in cancer.

Sample UMAP

• The sample UMAP displays a high degree of intermixing of cells from different samples within the broader cell type clusters. This indicates that potential batch effects originating from individual samples are largely mitigated, and the cell clustering is primarily driven by biological variation rather than technical artifacts. This is a positive sign for data integration and downstream analyses.

Cell Type UMAPs (Major, Minor, Subset)

• The celltype_major, celltype_minor, and celltype_subset UMAPs reveal well-defined and largely distinct clusters corresponding to different cell types.
• Intestinal Epithelial cells (Ent.Epi) form a large, distinct cluster in the lower-right region, indicating their unique transcriptional profile. This cluster is predominantly associated with the 'Tumor' condition, as seen in the condition UMAP.
• T cells (T cell, T cell CD4+, T cell CD8+) are distributed across several clusters, primarily in the central and upper-left regions, reflecting their heterogeneity and diverse states within the tissue.
• Myeloid cells (Myeloid, Macrophage) also form prominent clusters, often adjacent to T cell populations.
• Stromal cells (Stromal cell, Fibroblast, Smooth muscle cell) and Endothelial cells (Endothelial cell) form distinct, though sometimes smaller, clusters.
• B cells, Plasma cells, and Mast cells also form their own identifiable clusters.
• The unassigned cell population is minimal and scattered, suggesting a comprehensive and high-quality cell annotation.

Ploidy_dec UMAP

• The ploidy_dec UMAP shows a striking distribution of 'Aneuploid' cells, which form a large, concentrated cluster in the lower-right region. This cluster largely overlaps with the region identified as 'Intestinal Epithelial cell' in the celltype_major UMAP and the 'Tumor' condition in the condition UMAP.
• Conversely, 'Diploid' cells are broadly distributed across the other clusters, encompassing immune, stromal, and adjacent normal epithelial cells.
• The 'Unclear' category represents a very small fraction of cells, not forming any distinct clusters.

Biological Interpretation

The UMAP visualizations provide compelling insights into the cellular landscape of colorectal carcinoma:

• Disease-Specific Cell Compartmentation: The clear separation of 'Tumor' and 'Adj_normal' conditions on the UMAP strongly suggests significant changes in cellular composition and/or gene expression programs occur during colorectal tumorigenesis. This aligns with the known extensive remodeling of the tissue microenvironment in cancer.
• Robust Cell Type Identification: The well-separated clusters for major, minor, and subset cell types validate the quality and specificity of the cell type annotations. This robust annotation is critical for accurately dissecting the roles of different cell populations in health and disease.
• Identification of Tumor Cells via Ploidy: The most striking biological finding is the strong spatial association of 'Aneuploid' cells with the 'Intestinal Epithelial cell' cluster, which in turn largely corresponds to the 'Tumor' condition. This observation strongly supports the resolution that 'Intestinal Epithelial cell' is the tumor-origin cell type, and the aneuploidy status serves as a powerful indicator for identifying malignant epithelial cells. Aneuploidy is a hallmark of cancer, especially carcinomas, and its detection in specific epithelial clusters confirms their neoplastic nature [1].
• This provides crucial evidence for distinguishing malignant epithelial cells from normal or reactive epithelial cells within the dataset, which is a common challenge in single-cell cancer analyses.
• Heterogeneity of Immune and Stromal Cells: The distribution of immune cells (T cells, Myeloid cells, B cells) and stromal cells (Fibroblasts, Endothelial cells) across multiple clusters and their presence in both tumor and adjacent normal regions highlights their diverse states and roles within the complex tumor microenvironment. Further condition-specific analyses of these populations will likely reveal tumor-promoting or anti-tumor functions.

Annotation Notes

• The distinct clustering of cell types and the clear segregation of conditions indicate a high quality of data processing and annotation.
• The minimal presence of 'unassigned' cells and the successful integration of samples (lack of strong batch effects in the sample UMAP) enhance confidence in the downstream analyses.
• The strong correlation between aneuploidy and the identified tumor-origin epithelial cells provides strong validation for the malignancy status of these cells.

References

1. Aneuploidy in Cancer: For general information on aneuploidy as a hallmark of cancer.

• PubMed Search: aneuploidy cancer hallmark https://pubmed.ncbi.nlm.nih.gov/?term=aneuploidy+cancer+hallmark

2. UMAP Visualization of Major Cell Type Scores and Ploidy Status

[Analysis Visualization Results]...

Analysis Overview

This analysis presents UMAP visualizations depicting the distribution of various major cell types based on their HiCAT scores, alongside plots showing the ploidy status and overall major cell type assignments. These plots provide a global overview of the cellular landscape and help to validate cell type annotations and identify the location of aneuploid cell populations within the single-cell RNA-seq dataset from colon tissue.

Visual Summary

• Overall UMAP Structure: The UMAP projection effectively separates cells into distinct clusters, reflecting the heterogeneity of cell types within the colon tissue. Several major clusters are evident, indicating the presence of diverse cellular populations.

HiCAT Major Cell Type Scores:

• The HiCAT_major_score plots for most major cell types (e.g., T cell, Plasma cell, B cell, Myeloid cell, Mast cell, Endothelial cell, Stromal cell, Intestinal Epithelial cell) show clear enrichment in specific, localized regions of the UMAP. This indicates a high confidence in the assignment of these cell types to distinct transcriptional profiles and corresponding UMAP clusters.
• Intestinal Epithelial Cells: A large and well-defined cluster shows high scores for Intestinal Epithelial cell, predominantly located in the lower-central and right-hand regions of the UMAP.
• Immune Cells: T cells, B cells, Plasma cells, Myeloid cells, and Mast cells form distinct clusters, primarily distributed across the top-left, top-right, and central regions, suggesting their presence as immune infiltrates.
• Stromal and Endothelial Cells: Stromal cells and Endothelial cells also occupy well-defined, albeit smaller, clusters, mainly in the right-hand and upper-right regions.
• Enteric Neuron: The HiCAT_major_score: Enteric neuron plot shows very low scores and a diffuse distribution across the UMAP, suggesting either a very rare population or a less transcriptionally distinct profile for this cell type within this specific dataset, or potentially a non-robust annotation for this type.
• Ploidy Status (ploidy_dec): The ploidy_dec plot highlights a clear separation of ploidy states.
• A prominent cluster of Aneuploid cells (indicated in deep red) is observed, almost exclusively localizing to the large cluster that also exhibits high Intestinal Epithelial cell scores.
• The vast majority of the remaining cells are Diploid (indicated in light yellow), distributed across the other major UMAP clusters. A very small number of Unclear cells are present.
• Major Cell Type (celltype_major): This plot provides the final assignment of major cell types to each cluster. It largely corroborates the high-scoring regions seen in the individual HiCAT_major_score plots, confirming the distinct clustering of cell types such as Intestinal Epithelial cells, T cells, Myeloid cells, B cells, Plasma cells, Stromal cells, Endothelial cells, and Mast cells.

Biological Interpretation

The UMAP visualizations effectively delineate the cellular landscape of the colon tissue, providing strong evidence for the distinct transcriptional identities of major cell types.

• Robust Cell Type Annotation: The high concordance between the HiCAT_major_score plots and the celltype_major assignments suggests a robust and accurate annotation of the major cell populations. This is critical for subsequent downstream analyses, ensuring that cell-type-specific findings are reliable.
• Identification of Tumor Cells: The dataset context indicates that 'Intestinal Epithelial cell' is the resolved tumor-origin cell type for Colorectal Carcinoma. The ploidy_dec plot strongly supports this by showing that the Aneuploid cell population, a hallmark of cancer, predominantly co-localizes with the Intestinal Epithelial cell cluster. This provides clear visual evidence for the successful identification of the malignant epithelial cell population within the tumor microenvironment.
• Tumor Microenvironment Composition: Beyond the malignant epithelial cells, the presence of distinct clusters of various immune cells (T cells, B cells, Plasma cells, Myeloid cells, Mast cells) and stromal/endothelial cells confirms the heterogeneous nature of the tumor microenvironment in colorectal carcinoma. These non-malignant cells play crucial roles in tumor progression, immune response, and drug resistance.
• Potential for Minor Cell Populations or Annotation Refinement: The low and diffuse Enteric neuron score suggests that this cell type might be rare or have a less unique transcriptional signature in this specific dataset. While these plots confirm major cell type identities, further detailed sub-clustering and marker gene analysis would be necessary to fully resolve and validate minor or less distinctly separated populations.

Annotation Notes

The UMAP projections and cell type score visualizations provide strong support for the quality of the major cell type annotations. The distinct clustering and clear score enrichments for most cell types indicate that the embedding effectively captures the underlying biological differences between these populations. The congruence between the Intestinal Epithelial cell cluster and the Aneuploid population is a critical validation point in the context of colorectal carcinoma, confirming the resolution of the tumor cell compartment. The "unassigned" category also appears to be minimal, suggesting comprehensive coverage by the identified major cell types.

3. Marker Gene Expression Across Colon Cell Subsets

[Analysis Visualization Results]...

Analysis Overview

This analysis presents a marker gene expression dot plot for various celltype_subset populations derived from single-cell RNA-sequencing data of Colon tissue. The objective of this visualization is to assess the fidelity of cell type annotations by examining the expression patterns of known and discovered marker genes across these fine-grained cell subsets. The plot_markers_and_expression_dot tool was employed without specifying a particular target cell type, ensuring a comprehensive overview of marker expression. Markers were selected with a preference for surfaceome genes (as indicated by surfaceome_only: True in find_cfg), which are often relevant for cell sorting and therapeutic applications.

Visual Summary

The dot plot effectively visualizes the expression of 100 marker genes (columns) across 43 distinct celltype_subset groups (rows). Each dot's size corresponds to the fraction of cells within a given group that express a particular gene, while its color intensity represents the mean expression level of that gene within the group (redder indicates higher expression). Genes are organized by the celltype_subset they preferentially mark, indicated by the overarching black bars at the top. A distinct column labeled "common markers" at the far right highlights genes that are broadly expressed across multiple cell types. The accompanying bar chart on the right indicates the total number of cells assigned to each celltype_subset, providing a quantitative context for each population's representation.

Biological Interpretation

The marker gene expression patterns largely align with established biological knowledge for these cell types in the colon, providing strong support for the accuracy and granularity of the celltype_subset annotations.

• B cell Subsets: B cell (Breg), B cell (Follicular), B cell (MZ), and B cell (Memory) populations uniformly express classical B cell markers such as POU2F2, POU2AF1, CD19, CD79A, CD79B, and MS4A1 (CD20), confirming their B lymphoid identity.
• Endothelial Cell Heterogeneity: Endothelial cell, Endothelial tip cell, and Lymphatic Endothelial cell show distinct but related marker profiles. General endothelial markers like VWF, FLT1, CD34, ANGPT2, and EPHB2 are evident across endothelial groups, while PROX1 selectively marks Lymphatic Endothelial cell, consistent with its known role in lymphatic vessel development. DLL4 shows strong expression in Endothelial tip cell, highlighting its role in angiogenesis.
• Intestinal Epithelial Lineage: The various Intestinal Epithelial cell subsets, including Crypt cell, Enterocyte, Goblet cell, Microfold cell, Paneth cell, and Tuft cell, display highly specific marker expression. For instance, CDX1 and ASCL2 are enriched in Crypt cell (stem/progenitor-like), VIL1 and FABP1 in Enterocyte (absorptive), MUC2 and TFF3 in Goblet cell (mucin-secreting), LYZ in Paneth cell (antimicrobial), and DCLK1 in Tuft cell (chemosensory). This intricate pattern strongly validates the epithelial differentiation annotations.
• Mast Cells: The Mast cell population is clearly demarcated by high and specific expression of canonical markers such as KIT (CD117), TPSB2 (Tryptase beta 2), and CPA3 (Carboxypeptidase A3).
• Myeloid Cell Diversity: DC (Classical), DC (Inflammatory), DC (Plasmacytoid) subsets show differential expression of markers like FCER1A (general DC marker) and IRF7 (pDC-associated), affirming their distinct identities. Macrophage subsets (Macrophage (M1), Macrophage (M2A), M2B, M2C, M2D) broadly express CD68 and CD14, with more nuanced differences in markers like MSR1 and C1QA/B/C components, which help distinguish M2-like polarization states.
• Plasma Cells: Plasma cell annotation is robustly supported by highly specific expression of JCHAIN, MZB1, XBP1, PRDM1 (BLIMP1), and TNFRSF17 (BCMA), all critical for plasma cell differentiation and function.
• Stromal Cell Markers: Fibroblast and Smooth muscle cell groups exhibit characteristic stromal markers. Fibroblasts strongly express collagen genes (COL1A1, COL3A1, COL6A2), DCN, and LUM. Markers like ACTA2, MYH11, TAGLN, and TPM2 are highly expressed in Smooth muscle cell and also present in Fibroblast, which is consistent with the presence of myofibroblast populations or shared contractile machinery components.
• Innate Lymphoid Cells (ILCs): Distinct ILC subsets (ILC1, ILC2, ILC3) show expression of their defining transcription factors (e.g., GATA3 and RORA for ILC2, RORC for ILC3), supporting their unique functional identities within the innate immune system.
• NK Cells: NK cell populations are characterized by cytotoxic granule-associated proteins such as NKG7, GZMA, GZMB, PRF1, and the NK receptor KLRD1 (CD94).
• T Cell Lineages: Both T cell CD4+ and T cell CD8+ subsets show pan-T cell markers (CD3D, CD3E, CD3G). CD4 is specific to helper T cell subsets, while CD8A and CD8B are specific to cytotoxic T cell subsets. Sub-differentiation markers like FOXP3 (Treg), STAT1 (Th1), RORC (Th17), and GATA3 (Th2) further validate the annotation of specialized T helper cells. Cytotoxic T cells (T cell (Cytotoxic), T cell (CD8 Memory), T cell (CD8 Exhausted)) express high levels of effector molecules like GZMA, GZMB, and PRF1, with TIGIT being particularly enriched in T cell (CD8 Exhausted), indicating an exhaustion phenotype.

Annotation Notes

The detailed marker expression patterns provide strong evidence that the celltype_subset annotations are well-defined and biologically plausible, covering a broad spectrum of cell types expected in colorectal tissue. The approach of utilizing surfaceome-enriched markers is advantageous for potential follow-up validation experiments such as flow cytometry. While most cell type assignments are distinctly supported, some markers show expected overlap between functionally related cell types (e.g., stromal cells or different T helper cell subsets), reflecting true biological complexity rather than annotation ambiguity. The observed cell numbers per subset also provide valuable context, indicating the relative abundance of each cell type in the dataset.

4. Copy Number Variation Analysis in Intestinal Epithelial Cells

[Analysis Visualization Results]...

Analysis Overview

This analysis investigates copy number variation (CNV) patterns specifically within Intestinal Epithelial cell populations derived from single-cell RNA-seq data. The goal is to identify genomic alterations characteristic of tumor cells compared to adjacent normal cells in colorectal tissue. Intestinal Epithelial cell has been identified as the resolved tumor-origin cell type in this dataset. The results are presented as a heatmap visualizing log2(Copy Number Ratio) across genomic spots for individual samples and a summary heatmap showing the frequency of significant copy number amplifications in specific cytogenetic bands across tumor samples.

Visual Summary

CNV Heatmap (log2(CNR))

The first heatmap displays the log2(Copy Number Ratio) for Intestinal Epithelial cell clusters across approximately 1700 genomic spots, grouped by sample.

• Adjacent Normal Samples (Adj_norm Cxxx): Cells from adjacent normal colon tissue samples (top section) generally exhibit a stable genomic profile, with log2(CNR) values centered around zero (indicated by light yellow/green), signifying a largely diploid state with no widespread copy number alterations. This serves as a critical baseline for comparison.
• Diploid Tumor Samples (Diploid Tumor Cxxx): A distinct block of samples labeled Diploid Tumor shows a mixed pattern. While generally less altered than the Tumor group, these samples still present noticeable regions of amplification (red) and deletion (blue) in specific genomic regions, such as gains on chromosome 7, 8, and 20. This suggests that even cells designated as 'Diploid Tumor' can harbor significant focal CNVs or reflect a different ploidy status at the single-cell level compared to a global sample assessment.
• Tumor Samples (Tumor Cxxx): The largest block of samples, simply labeled Tumor, displays widespread and heterogeneous patterns of copy number alterations. These samples are characterized by extensive genomic instability, with numerous and often large regions of amplification (red) and deletion (blue). Common regions of gain include large segments of chromosomes 7, 8q, 13q, and 20q, while regions such as 8p and 18q frequently show deletions. The extent and specific patterns of CNVs vary considerably among individual tumor samples, highlighting intratumoral and interpatient genomic heterogeneity.

Significant CNV Amplification Frequency Heatmap

The second heatmap summarizes the frequency of significant copy number amplifications across various cytogenetic bands, specifically focusing on Tumor samples.

• Each column represents a distinct tumor sample (Tumor C105 to Tumor C173), and each row corresponds to a specific cytoband.
• The color intensity (from light to dark blue) indicates the frequency of amplification within that cytoband for each sample, with darker blue representing higher frequency.
• Highly Recurrent Amplifications: Several cytogenetic bands show high-frequency amplifications across a significant proportion of tumor samples. Notably, the most frequently amplified regions include:
• 7p11.2 (EGFR): This region, containing the *EGFR* gene, is frequently amplified across many tumor samples.
• 8q24.21 (MYC): Amplification of the *MYC* oncogene locus is also highly prevalent.
• 20q13.33: This distal region of chromosome 20q exhibits consistent amplification.
• 17q12 (ERBB2): The *ERBB2* (HER2) gene locus shows recurrent amplification in a subset of samples.
• 13q34: Another frequently amplified region, likely harboring multiple oncogenes.
• Inter-sample Variability: While certain amplifications are common, the heatmap also reveals heterogeneity. Some samples exhibit many amplifications across various bands (e.g., Tumor C158, C169), while others show a more restricted set of amplifications. The overall frequency of amplification for each cytoband across all tumor samples is summarized in the rightmost column, confirming the high recurrence of the regions mentioned above.

Biological Interpretation

The observed CNV patterns provide clear biological insights into colorectal carcinoma:

• Genomic Instability in Cancer: The profound difference in CNV profiles between Adj_normal and Tumor Intestinal Epithelial cell populations is a hallmark of cancer. Normal cells maintain genomic integrity, while tumor cells display widespread genomic alterations, a primary driver of oncogenesis and tumor progression.
• Tumor-Origin Cell Type Confirmation: The detection of extensive and recurrent CNVs in Intestinal Epithelial cell reinforces its identification as the tumor-origin cell type, confirming that these cells are indeed malignant and contribute to the tumor's bulk.
• Oncogene Amplifications: The recurrent amplifications of specific oncogenes highlight critical drivers in colorectal cancer pathogenesis:
• _EGFR_ (7p11.2): Amplification of the Epidermal Growth Factor Receptor gene is a well-established oncogenic event, leading to increased cell proliferation, survival, and metastasis. EGFR signaling is a key pathway in many cancers, including CRC. GeneCards: EGFR
• _MYC_ (8q24.21): The proto-oncogene _MYC_ is a potent regulator of cell growth and division. Its amplification promotes uncontrolled cell proliferation, making it a significant oncogenic driver in CRC. GeneCards: MYC
• _ERBB2_ (17q12): Also known as HER2, _ERBB2_ amplification drives aggressive tumor phenotypes in a subset of CRC and other cancers. GeneCards: ERBB2
• Tumor Heterogeneity: The variability in CNV profiles across different tumor samples underscores the genomic heterogeneity of colorectal carcinoma, which can affect disease progression, response to therapy, and potential for relapse.
• Ploidy Status Nuance: The Diploid Tumor samples, despite their 'Diploid' label, show focal CNVs. This suggests that while a global ploidy assessment might classify these cells as diploid, single-cell resolution reveals localized genomic alterations that are characteristic of tumor cells. This emphasizes the importance of single-cell CNV analysis for a comprehensive understanding of genomic instability, even in ostensibly diploid tumors.

Clinical or Translational Implications

• Biomarker Identification: The identified recurrent amplifications, particularly of oncogenes like _EGFR_, _MYC_, and _ERBB2_, serve as crucial biomarkers. These could be used for molecular subtyping of colorectal cancer, predicting disease aggressiveness, and potentially guiding prognosis.
• Targeted Therapy Opportunities: The amplification of _EGFR_ and _ERBB2_ has direct implications for targeted therapies. Patients with _EGFR_ amplification might respond to anti-EGFR therapies (e.g., cetuximab, panitumumab), while those with _ERBB2_ amplification could benefit from anti-HER2 agents (e.g., trastuzumab, pertuzumab), provided these are indicated for CRC and further validated.
• Personalized Medicine: Understanding the specific CNV landscape of a patient's tumor at a single-cell level can facilitate more precise and personalized treatment strategies, moving beyond broad classifications to target specific molecular vulnerabilities.
• Monitoring Tumor Evolution: The detected genomic instability and heterogeneity highlight the dynamic nature of cancer. Monitoring CNVs could potentially offer insights into tumor evolution, development of drug resistance, and identification of actionable targets during treatment.
• Annotation Validation: The clear CNV distinctions between adjacent normal and tumor Intestinal Epithelial cell populations robustly validates the cell type annotations and the accurate separation of malignant cells from healthy tissue.

5. UMAP Visualization of CNV Patterns across Cell Types, Ploidy, Condition, and Samples

[Analysis Visualization Results]...

Analysis Overview

This analysis presents five Uniform Manifold Approximation and Projection (UMAP) plots, where the embedding space (X_cnv_umap1, X_cnv_umap2) is specifically derived from Cell-type-specific Copy Number Variation (CNV) patterns. Each UMAP visualizes the distribution of cells, colored by different metadata categories: celltype_major, celltype_minor, ploidy_dec (ploidy declaration), condition (Tumor vs. Adj_normal), and sample (individual patient samples). The primary goal is to understand how cells cluster based on their CNV profiles and how these clusters correlate with biological and clinical annotations, particularly in the context of colorectal carcinoma.

Visual Summary

1. CNV-driven UMAP Structure and Ploidy Status

The UMAP embedding clearly segregates cells into distinct compartments based on their CNV profiles.

• ploidy_dec UMAP: This plot shows a striking separation. A large, cohesive cluster occupying the left and bottom regions of the UMAP is predominantly composed of Diploid cells (light yellow). In contrast, a distinct and somewhat more dispersed cluster, primarily located in the right and top regions, is overwhelmingly populated by Aneuploid cells (dark red). Cells labeled Unclear are sparse and scattered. This strong separation confirms that the CNV-based embedding successfully differentiates cells based on their ploidy status.

2. Condition-specific Segregation

• condition UMAP: This UMAP mirrors the ploidy_dec plot almost perfectly. The Diploid region from the ploidy UMAP largely corresponds to cells from Adj_normal tissue (maroon/purpleish-brown). The Aneuploid region, on the other hand, is predominantly composed of cells from Tumor tissue (blue/greenish-blue). This indicates a strong correlation between aneuploidy and the tumor condition, as expected in malignancy. While there is a clear distinction, some intermingling is observed at the interface, likely representing infiltrating non-malignant cells within the tumor microenvironment or stromal cells that have not undergone aneuploidy.

3. Cell Type Distribution

• celltype_major UMAP: This plot provides critical insight into cellular composition within the CNV-defined compartments.
• The Diploid/Adj_normal cluster shows a rich diversity of Myeloid cell (light yellow), T cell (blue), B cell (dark red), Stromal cell (mint green), Endothelial cell (orange), and Plasma cell (pink) populations.
• Crucially, the Aneuploid/Tumor cluster (right/top) is almost exclusively dominated by Intestinal Epithelial cell (orange-yellow). This strongly indicates that the malignant cells driving the aneuploid signature are of intestinal epithelial origin.
• Other cell types (e.g., T cells, myeloid cells) are also present in the tumor compartment, reflecting the immune and stromal components of the tumor microenvironment, but they do not form the core of the aneuploid cluster.
• celltype_minor UMAP: This plot reinforces the celltype_major findings with finer granularity. Intestinal Epithelial cell (orange-yellow) continues to be the primary cell type in the aneuploid/tumor region. Immune cells like Macrophage, T cell CD4+, T cell CD8+, along with Fibroblast and Endothelial cell populations, are distributed across both the diploid/adjacent normal and aneuploid/tumor regions, consistent with their presence in both healthy tissue and the tumor microenvironment.

4. Sample-level Heterogeneity

• sample UMAP: This plot reveals considerable inter-sample variability, particularly within the Aneuploid/Tumor compartment. Different tumor samples (various shades of green and blue) form distinct, although sometimes overlapping, sub-clusters within the broad aneuploid region. This suggests unique CNV landscapes or tumor-specific genomic alterations across individual patients. The Adj_normal region (various shades of red/orange) also shows some sample-specific patterns, but they appear more integrated, indicating a more conserved genomic profile in normal tissues compared to the highly variable tumor genomic landscape.

Biological Interpretation

These UMAPs provide a comprehensive view of cellular heterogeneity based on CNV patterns in colorectal carcinoma. The embedding successfully separates tumor cells from non-malignant cells, primarily driven by the presence of aneuploidy and other CNVs.

1. Tumor Cell Identification: The analysis unequivocally identifies Intestinal Epithelial cell as the primary malignant cell population within the tumor samples, consistent with the Resolved tumor-origin cell type provided in the data context and the known etiology of colorectal carcinoma (adenocarcinoma arising from epithelial cells) GeneCards: Colon Cancer. These cells exhibit pronounced aneuploidy, forming a distinct cluster in the CNV-driven UMAP space.
2. Tumor Microenvironment (TME): While the malignant cells form a clear aneuploid cluster, other cell types (e.g., T cells, B cells, macrophages, fibroblasts, endothelial cells) are observed within the Tumor condition region. These cells typically maintain a diploid genomic status and represent the critical immune and stromal components of the TME, which play crucial roles in tumor progression, angiogenesis, and immune surveillance PubMed search: Tumor Microenvironment Colorectal Cancer. Their clustering outside the core aneuploid region, even within the tumor sample context, highlights that their CNV profiles are distinct from the malignant epithelial cells.
3. Genomic Heterogeneity: The sample UMAP vividly illustrates the patient-specific genomic heterogeneity in colorectal cancer. The observation that individual tumor samples cluster distinctly within the aneuploid compartment suggests varied CNV landscapes across patients, reflecting diverse evolutionary paths and genomic instability patterns PubMed search: Colorectal Cancer Genomic Heterogeneity. This heterogeneity has significant implications for understanding disease progression and designing personalized therapeutic strategies.

Annotation Notes

The strong separation based on ploidy_dec and condition confirms the robust nature of the CNV estimation and the effectiveness of the CNV-aware UMAP embedding. The celltype_major and celltype_minor annotations are well-supported by the distinct clustering of Intestinal Epithelial cell in the aneuploid, tumor-specific compartment. The remaining diverse immune and stromal cell types are appropriately distributed, indicating sound cell type identification. The sample UMAP provides valuable insight into inter-patient variability, a key characteristic in cancer research, without obscuring the general patterns. Overall, the annotations appear consistent with the biological context and the observed CNV patterns.

6. Minor Cell Type Population Analysis in Colorectal Carcinoma

[Analysis Visualization Results]...

Analysis Overview

This analysis presents a stacked bar plot visualizing the relative proportions of different minor cell types across individual samples, comparing adjacent normal colon tissue (Adj_normal) with colorectal tumor tissue (Tumor). Each bar represents a single sample, and the colored segments within each bar denote the percentage contribution of each identified minor cell type. This visualization provides insights into the cellular composition of the tumor microenvironment (TME) compared to healthy tissue, highlighting potential shifts associated with colorectal carcinoma.

Visual Summary

The stacked bar plots illustrate distinct differences in cellular composition between adjacent normal and tumor samples from the colon.

• Intestinal Epithelial Cell Dynamics: In adjacent normal tissues, Intestinal Epithelial cells (light orange/orange) constitute a substantial proportion, often dominating the cellular landscape. In contrast, tumor samples generally show a relatively lower proportion of Intestinal Epithelial cells. This relative decrease is notable, especially considering that Intestinal Epithelial cells are the resolved tumor-origin cell type, suggesting a significant infiltration and expansion of non-epithelial cells within the tumor.

Immune Cell Infiltration:

• T cells (CD4+ and CD8+): Both T cell CD4+ (light green) and T cell CD8+ (teal blue) populations appear more prominent and constitute a larger relative proportion in many tumor samples compared to adjacent normal tissues. This indicates increased immune cell infiltration into the tumor microenvironment.
• Macrophages: Macrophages (light yellow) also show an increased relative abundance in tumor samples, suggesting an expansion of myeloid cell populations within the TME.
• Plasma cells: Plasma cells (light green-yellow) also appear to have an increased presence in several tumor samples.

Stromal Cell Expansion:

• Fibroblasts: Fibroblasts (light coral) generally exhibit a noticeable increase in their relative proportion in tumor samples, consistent with stromal remodeling.
• Heterogeneity: Substantial sample-to-sample variability in cell type proportions is observed within both the "Adj_normal" and "Tumor" groups, reflecting biological heterogeneity among individuals.
• Unassigned Cells: A small fraction of cells remains "unassigned" in both conditions, which is typical for single-cell analyses and does not obscure major trends.

Biological Interpretation

The observed shifts in minor cell type populations provide critical insights into the pathophysiology of colorectal carcinoma:

• Tumor Microenvironment Remodeling: The relative reduction of Intestinal Epithelial cells in tumor samples, despite being the transformed cell type, is a common feature of carcinoma. It often reflects the extensive infiltration and proliferation of immune and stromal cells that collectively form the tumor microenvironment, effectively 'diluting' the epithelial component in terms of relative proportion.

Immune Landscape in CRC:

• The increased infiltration of T cells (CD4+ and CD8+) into the tumor is a crucial aspect of the anti-tumor immune response. CD8+ T cells are cytotoxic and mediate direct killing of cancer cells, while CD4+ T cells play diverse roles, including helper functions (Th1, Th2, Th17) and regulatory functions (Treg). The balance and functional state of these subsets are critical for determining overall anti-tumor immunity versus immune evasion [PubMed: T cells in cancer immunotherapy].
• The significant increase in Macrophages in tumor samples is characteristic of Tumor-Associated Macrophages (TAMs). TAMs are highly plastic and are often polarized towards M2-like phenotypes, which can promote tumor growth, angiogenesis, metastasis, and immunosuppression within the colorectal cancer microenvironment [GeneCards: Macrophages in Cancer, PubMed: Tumor-associated macrophages in colorectal cancer].
• The increased presence of Plasma cells can reflect both active humoral immune responses against the tumor or contribute to pro-tumor inflammation depending on their specific subtypes and the immune context [PubMed: Plasma cells in colorectal cancer].
• Cancer-Associated Fibroblasts (CAFs): The expansion of Fibroblasts in the tumor suggests the presence of Cancer-Associated Fibroblasts (CAFs). CAFs are key players in stromal remodeling, contributing to extracellular matrix deposition, creating a pro-tumorigenic niche, facilitating tumor cell invasion, and suppressing immune responses in CRC [PubMed: Cancer-associated fibroblasts in colorectal cancer].

Clinical or Translational Implications

The changes in cell type composition identified here have several clinical and translational implications for colorectal carcinoma:

• Prognostic Biomarkers: The relative abundance of specific immune and stromal cell populations in the tumor microenvironment can serve as prognostic indicators. For example, a high infiltration of cytotoxic CD8+ T cells is often associated with a better prognosis in CRC, while a high density of TAMs or CAFs can correlate with poorer outcomes [PubMed: Prognostic value of immune cell infiltration in colorectal cancer].

Therapeutic Targets:

• The increased presence of TAMs and CAFs suggests that targeting these stromal components could be a viable therapeutic strategy to inhibit tumor growth and reduce immunosuppression.
• The prominent infiltration of T cells highlights the potential for immunotherapeutic interventions, such as immune checkpoint inhibitors, which aim to reactivate anti-tumor T cell responses. Further detailed analysis of T cell subsets and their exhaustion markers would be beneficial.
• Patient Stratification: Understanding the cellular composition of individual tumors can aid in stratifying patients for different treatment modalities. Patients with a highly inflamed (T cell-rich) tumor microenvironment might respond better to immunotherapies, while those with a more stromal-rich (CAF-rich) or myeloid-dominant (TAM-rich) TME might benefit from therapies targeting those specific cell types or pathways.

7. T cell and Innate Lymphoid Cell Subpopulation Analysis in Colorectal Carcinoma

[Analysis Visualization Results]...

Analysis Overview

This analysis presents a population bar plot illustrating the relative proportions of various T cell subsets, NK cells, and Innate Lymphoid Cells (ILCs) across individual patient samples. Samples are categorized into 'Adj_normal' (adjacent normal colon tissue) and 'Tumor' (colorectal carcinoma tissue) conditions. The plot provides a comprehensive view of the lymphoid cell compartment within the tissue microenvironment for each sample, allowing for comparison between healthy and cancerous states.

Visual Summary

The stacked bar plots display the proportional distribution of 21 distinct lymphocyte subsets across multiple individual samples, separated by condition. Each bar represents a single sample, with subsets colored according to the provided legend.

• Adjacent Normal Tissue (Adj_normal): The lymphoid compartment in adjacent normal tissue samples is predominantly composed of T cell (CD4 Memory), T cell (CD8 Memory), and T cell (Cytotoxic) populations, forming a significant portion of the total T cell infiltrate. T cell (CD4 Naive) and T cell (CD8 Naive) are also present. Regulatory T cells (Treg), various T helper (Th) subsets (Th1, Th2, Th9, Th17, Th22, Tfh), NK cells, and ILCs (ILC1, ILC2, ILC3, ILCreg) are observed in smaller, yet variable, proportions across samples.
• Tumor Tissue (Tumor): In contrast to adjacent normal tissue, tumor samples exhibit a marked shift in the lymphoid cell composition.
• Increased Regulatory T cells (Treg): A striking observation is the substantial increase in the proportion of T cell (Treg) (dark blue segments) across nearly all tumor samples. In many tumor samples, Tregs constitute a significantly larger fraction compared to adjacent normal tissue.
• Increased T cell (CD8 Exhausted): The proportion of T cell (CD8 Exhausted) (pale yellow/cream segments) also appears to be higher in tumor samples. This subset often represents a considerable portion of the CD8+ T cell population in the tumor microenvironment.
• Variable Effector T cells: While T cell (CD4 Memory) and T cell (CD8 Memory) remain substantial, their relative contribution might be diminished in some tumor samples due to the expansion of Tregs and exhausted CD8+ T cells. T cell (Cytotoxic) populations, which are key anti-tumor effectors, show variable proportions but are often less prominent than the exhausted CD8+ T cells.
• Other Subsets: The proportions of NK cells and various T helper subsets (Th1, Th2, Th17, Th22, Th9, Tfh) appear more heterogeneous across individual tumor samples. ILCs (dark red hues) remain relatively minor components, similar to the normal tissue.
• Inter-sample Variability: Both conditions show considerable sample-to-sample variability in the exact proportions of each subset, but the trends described above for Treg and CD8 Exhausted T cells are consistent across the majority of tumor samples.

Biological Interpretation

The observed shifts in T cell subset populations between adjacent normal and tumor tissues provide critical insights into the immune landscape of Colorectal Carcinoma (CRC).

• Immune Evasion via Regulatory T cells (Tregs): The significant increase in T cell (Treg) populations within the tumor microenvironment is a well-established mechanism of immune evasion in many cancers, including CRC [1]. Tregs are potent immunosuppressive cells that inhibit the activity of effector T cells (like cytotoxic T lymphocytes) and other immune cells, thereby promoting tumor growth and preventing effective anti-tumor immune responses. Their elevated presence suggests an actively immunosuppressive environment within the colon tumors.
• T cell Exhaustion in the Tumor Microenvironment: The increased proportion of T cell (CD8 Exhausted) is characteristic of chronic antigen exposure and persistent inflammation, commonly found in the tumor microenvironment. Exhausted CD8+ T cells are functionally impaired, losing their ability to proliferate, secrete cytokines, and efficiently kill target cells, despite recognizing tumor antigens [2]. This exhaustion state can be induced by continuous antigen stimulation, chronic inflammatory signals, and inhibitory receptor signaling (e.g., PD-1, CTLA-4). The co-occurrence of high Tregs and exhausted CD8+ T cells points to a profoundly immunosuppressed state that hampers anti-tumor immunity.
• Compromised Effector Function: While effector T cells (such as T cell (Cytotoxic)) are still present, their relative proportion may be overshadowed by the expanding immunosuppressive and exhausted populations. This imbalance implies a dysfunctional immune response against the tumor.
• Diversity of T Helper Responses: The presence of various Th subsets (Th1, Th17, Th2, etc.) indicates a complex adaptive immune response. The specific balance between pro-inflammatory (e.g., Th1) and potentially pro-tumorigenic (e.g., Th2 in some contexts) or context-dependent (e.g., Th17) Th responses can influence disease progression. However, the dominant shifts towards Tregs and exhausted CD8+ T cells suggest that even if pro-inflammatory Th cells are present, their efficacy may be compromised.

Clinical or Translational Implications

These findings have important implications for understanding CRC pathogenesis and for developing immunotherapeutic strategies:

• Immunosuppressive Tumor Microenvironment: The data clearly indicates an immunosuppressive tumor microenvironment in CRC, largely driven by the expansion of Tregs and the exhaustion of CD8+ T cells. This explains why many CRC patients may not respond to immunotherapies that require robust T cell activation.
• Potential Therapeutic Targets: Targeting Tregs (e.g., via depletion or inhibition of their function) and reversing T cell exhaustion (e.g., through immune checkpoint blockade) are promising strategies for revitalizing anti-tumor immunity in CRC. The high proportion of Tregs suggests that therapies aimed at modulating Treg activity could be particularly impactful.
• Biomarker Potential: The specific proportions and ratios of these T cell subsets (e.g., Treg/CD8+ T cell ratio, proportion of exhausted CD8+ T cells) could serve as predictive or prognostic biomarkers for disease progression, recurrence, or response to immunotherapy in CRC patients [3].
• Personalized Medicine: Understanding the specific immune cell infiltration patterns in individual patient tumors could guide personalized treatment approaches, selecting patients most likely to benefit from specific immunomodulatory therapies.

---

References

1. Regulatory T cells in cancer:

• PubMed search: "colorectal cancer regulatory T cells immune evasion" - https://pubmed.ncbi.nlm.nih.gov/?term=colorectal+cancer+regulatory+T+cells+immune+evasion

2. T cell exhaustion:

• PubMed search: "T cell exhaustion cancer immune checkpoint" - https://pubmed.ncbi.nlm.nih.gov/?term=T+cell+exhaustion+cancer+immune+checkpoint

3. Prognostic value of T cell subsets in CRC:

• PubMed search: "colorectal cancer T cell subsets prognosis immunotherapy" - https://pubmed.ncbi.nlm.nih.gov/?term=colorectal+cancer+T+cell+subsets+prognosis+immunotherapy

8. Differential T Cell Subset Proportions in Colorectal Carcinoma

[Analysis Visualization Results]...

Analysis Overview

This analysis investigates the proportional representation of various T cell and NK cell subsets within colorectal carcinoma (Tumor) tissue compared to adjacent normal (Adj_normal) tissue, using single-cell RNA-seq data. The goal is to identify T cell populations that show statistically significant differences in their proportions between these two conditions, providing insights into the immune microenvironment of colorectal cancer.

Visual Summary

The box plots display the celltype proportion for eight distinct T cell subsets and NK cells, comparing Tumor and Adj_normal conditions. Each panel indicates a statistically significant difference (p-value < 0.05).

1. Treg: Shows a highly significant increase (p=6.9e-18) in proportion within the Tumor samples compared to Adj_normal. The median proportion of Tregs is notably higher in tumors.
2. T cell (CD8 Memory): Exhibits a significant decrease (p=3.65e-05) in proportion in Tumor samples compared to Adj_normal. The median proportion is lower in the tumor microenvironment.
3. Th17: Demonstrates a significant increase (p=6.26e-05) in proportion within Tumor samples. The median proportion of Th17 cells is elevated in tumors.
4. Th22: Shows a significant increase (p=0.000244) in proportion in Tumor samples compared to Adj_normal.
5. T cell (CD8 Exhausted): Presents a significant increase (p=0.000696) in proportion within Tumor samples compared to Adj_normal.
6. T cell (CD4 Naive): Displays a significant decrease (p=0.00531) in proportion in Tumor samples relative to Adj_normal.
7. NK: Shows a significant increase (p=0.0125) in proportion within Tumor samples compared to Adj_normal.
8. Th9: Exhibits a significant increase (p=0.0207) in proportion in Tumor samples compared to Adj_normal, although the overall proportions for this subset are very low in both conditions.

In summary, the tumor microenvironment is characterized by an increase in immune suppressive (Treg, CD8 Exhausted) and certain pro-inflammatory/pro-tumorigenic (Th17, Th22, Th9) T cell subsets, along with an increased presence of NK cells. Conversely, crucial anti-tumor effector/memory T cell populations like CD8 Memory T cells and naive CD4 T cells are reduced.

Biological Interpretation

The observed shifts in T cell and NK cell proportions provide critical insights into the immune landscape of colorectal carcinoma.

• Immune Suppression and Evasion: The striking increase in Treg cells and T cell (CD8 Exhausted) populations within tumors is a hallmark of immune evasion. Tregs actively suppress anti-tumor immune responses, allowing cancer cells to escape destruction. CD8 T cell exhaustion, characterized by loss of effector function, arises from chronic antigen exposure in the tumor microenvironment and renders these critical anti-tumor cells ineffective. This combination signifies a heavily immunosuppressive environment that hinders effective anti-tumor immunity [1].
• Impaired Anti-Tumor Immunity: The decrease in T cell (CD8 Memory) and T cell (CD4 Naive) proportions in tumors suggests a compromised ability to mount and maintain robust anti-tumor responses. CD8 memory T cells are crucial for long-term protection, and their reduction may indicate their dysfunction, exclusion, or conversion to exhausted states within the TME. A reduction in naive T cells could imply altered immune cell recruitment or differentiation dynamics, potentially limiting the generation of new tumor-specific effector cells.
• Inflammation and Tumor Progression: The increase in Th17, Th22, and Th9 cells in the tumor is complex. While these subsets can have dual roles, in many cancer contexts, including colorectal carcinoma, Th17 and Th22 cells are often associated with chronic inflammation that promotes tumor growth, angiogenesis, and metastasis [2]. Th9 cells, while less studied, can also contribute to pro-tumorigenic inflammation or anti-tumor immunity depending on the specific context and cytokine milieu.
• NK Cell Recruitment/Alteration: The increased proportion of NK cells in the tumor microenvironment is intriguing. While NK cells are potent anti-tumor effectors, their mere presence does not guarantee function. In many cancers, tumor-infiltrating NK cells are functionally impaired due to various inhibitory signals within the TME, leading to an "NK cell paradox" where increased numbers do not equate to effective tumor control [3]. Further functional analysis would be necessary to determine the activation state and anti-tumor efficacy of these NK cells.

Overall, the findings paint a picture of an immune microenvironment in colorectal carcinoma that is characterized by substantial T cell remodeling, favoring immune tolerance and exhaustion while potentially suppressing effective anti-tumor surveillance.

Clinical or Translational Implications

These findings have several important clinical and translational implications for colorectal carcinoma:

• Biomarkers for Prognosis: The observed shifts in T cell subsets, particularly the enrichment of Tregs and exhausted CD8 T cells, could serve as prognostic biomarkers. High Treg infiltration is often associated with poorer outcomes in various cancers, including CRC, due to their immunosuppressive activity. Similarly, the degree of CD8 T cell exhaustion can correlate with response to immunotherapy.
• Targets for Immunotherapy: The pronounced immune suppression evidenced by increased Tregs and exhausted CD8 T cells highlights potential targets for therapeutic intervention. Strategies aimed at depleting Tregs, inhibiting their function, or reversing CD8 T cell exhaustion (e.g., checkpoint blockade therapies like anti-PD-1/PD-L1) could enhance anti-tumor immunity in CRC.
• Modulating Inflammation: The increased proportions of Th17, Th22, and Th9 cells suggest that modulating the inflammatory milieu could be a therapeutic avenue. However, given their context-dependent roles, careful consideration of downstream effects is essential.
• Enhancing NK Cell Function: While NK cells are increased in proportion, their functionality in the tumor microenvironment might be compromised. Therapies focused on restoring or boosting NK cell effector functions, such as cytokine therapy or adoptive NK cell transfer, could be beneficial.

These proportional changes provide a foundation for further in-depth investigations into the functional states of these immune cells and their precise contributions to colorectal cancer progression and response to therapy.

---

References:

[1] Regulatory T Cells and Immune Checkpoint Blockade: A PubMed search on "Treg exhaustion T cell colorectal cancer" can provide relevant reviews. [PubMed Search]

[2] Th17 and Th22 Cells in Cancer: A PubMed search on "Th17 Th22 colorectal cancer inflammation" for reviews. [PubMed Search]

[3] NK Cells in Tumor Microenvironment: A PubMed search on "NK cell dysfunction colorectal cancer" for general context. [PubMed Search]

9. Macrophage Subset Population Analysis in Colorectal Carcinoma

[Analysis Visualization Results]...

Analysis Overview

This analysis presents a population bar plot illustrating the relative proportions of various macrophage subsets (Macrophage (M1), Macrophage (M2A), Macrophage (M2B), Macrophage (M2C), and Macrophage (M2D)) within individual samples from both "Adj_normal" (adjacent normal colon tissue) and "Tumor" (colorectal carcinoma tissue) conditions. Each bar represents a single sample, and the stacked segments within each bar show the percentage contribution of each macrophage subset. This visualization allows for a direct comparison of macrophage polarization states between normal and tumor microenvironments at a granular sample level.

Visual Summary

The bar plot is divided into two main panels: "Adj_normal" on the left and "Tumor" on the right, each displaying the macrophage subset composition for multiple individual samples.

• Adj_normal Samples: In the adjacent normal colon tissue samples, there is a diverse representation of macrophage subsets. While Macrophage (M1) (dark red) is present, other M2-like subsets, specifically Macrophage (M2A) (orange-red), Macrophage (M2B) (light yellow), Macrophage (M2C) (pale yellow), and Macrophage (M2D) (teal/mint green), collectively constitute significant proportions of the macrophage population in many samples. The distribution appears more heterogeneous across samples, with no single subset consistently dominating to the same extent as observed in tumor samples.
• Tumor Samples: A striking shift in macrophage subset composition is observed in the tumor samples. Macrophage (M1) (dark red) becomes the predominant subset in a large majority of the tumor samples, often representing over 50% and frequently approaching 80-100% of the total macrophage population within a sample. Correspondingly, the proportions of M2-like macrophages (M2A, M2B, M2C, M2D) are substantially reduced or nearly absent in many of these M1-dominant tumor samples. While some tumor samples still show a mixed population, the trend towards M1 macrophage enrichment is a consistent and prominent feature of the colorectal tumor microenvironment in this dataset.

Biological Interpretation

Macrophages are highly plastic immune cells that can adopt distinct functional phenotypes in response to microenvironmental cues. These phenotypes are broadly categorized as M1 (classically activated) and M2 (alternatively activated), each with specific roles in immune responses and tissue homeostasis.

• M1 Macrophages: Generally considered pro-inflammatory and anti-tumorigenic. They are crucial for host defense against pathogens, characterized by high production of pro-inflammatory cytokines (e.g., TNFα, IL-1β, IL-6, IL-12) and potent cytotoxic activity against tumor cells via reactive oxygen and nitrogen species production [PubMed Search: M1 macrophage function cancer].
• M2 Macrophages: Often associated with anti-inflammatory, pro-tumorigenic functions, collectively known as Tumor-Associated Macrophages (TAMs). M2 macrophages promote tissue repair, angiogenesis, immune suppression, and metastasis. They are typically divided into further subsets (M2A, M2B, M2C, M2D) with nuanced roles:
• M2A: Involved in wound healing and tissue repair, often induced by IL-4/IL-13.
• M2B: Immunomodulatory, induced by immune complexes and IL-1β.
• M2C: Immunosuppressive, associated with chronic inflammation, induced by IL-10 or glucocorticoids. These are often highly abundant TAMs [PubMed Search: M2 macrophage subtypes tumor].
• M2D: Also known as TAMs, promote angiogenesis and metastasis, often induced by adenosine/TLR signaling.

The observed dominance of Macrophage (M1) cells in the colorectal tumor microenvironment is a significant finding. In many solid tumors, including colorectal carcinoma, TAMs are frequently skewed towards an M2-like phenotype, which facilitates tumor progression and immune evasion. Therefore, the prominent M1 polarization seen in this dataset suggests a potentially strong anti-tumor immune response or a specific M1-like state induced within these colon tumors. This could indicate:

1. Active Anti-Tumor Immunity: The presence of M1-dominant macrophages could signify an activated immune state capable of tumoricidal activity, which might correlate with a more favorable prognosis or responsiveness to certain immunotherapies.
2. Tumor Heterogeneity: While M1 dominance is a strong trend, the sample-to-sample variability indicates that some tumors may still harbor mixed or M2-biased macrophage populations, highlighting the inherent heterogeneity of the tumor microenvironment.
3. Context-Dependent M1 Phenotype: It is also possible that even M1-classified macrophages within the complex tumor microenvironment might exhibit plasticity or be subject to suppressive signals from other immune or stromal cells, leading to a phenotype that is not fully tumoricidal. Further functional characterization would be necessary to fully elucidate their precise roles.

Clinical or Translational Implications

The distinct shift towards M1 macrophage dominance in colorectal tumor samples has several potential clinical and translational implications:

• Prognostic Biomarker: The relative proportion of M1 macrophages, or the M1/M2 ratio, could serve as a valuable prognostic biomarker for colorectal cancer patients. M1 dominance might be associated with improved patient outcomes, although this requires correlation with clinical data.
• Immunotherapy Response Prediction: Patients with M1-dominant tumors might respond differently to existing or novel immunotherapies, such as immune checkpoint inhibitors. Understanding this polarization could help stratify patients for more targeted therapeutic approaches.
• Therapeutic Targeting: If M1 macrophages are indeed mediating anti-tumor activity, therapeutic strategies could focus on enhancing M1 polarization, maintaining their activated state, or preventing M1-to-M2 conversion within the tumor microenvironment. Conversely, if these M1-like cells are found to be dysfunctional, strategies to reactivate them would be explored.
• Monitoring Disease Progression: Changes in macrophage polarization could potentially be monitored over time to assess disease progression or response to treatment, offering a dynamic biomarker for clinical management.

10. Macrophage Subset Population Shifts in Colorectal Carcinoma

[Analysis Visualization Results]...

Analysis Overview

This analysis investigates the proportions of various macrophage subsets (derived from the celltype_subset annotation) in two distinct conditions: "Adj_normal" (adjacent normal colon tissue) and "Tumor" (colorectal tumor tissue). The objective was to identify macrophage subsets that exhibit statistically significant differences in their proportional representation between these conditions within the Colon tissue context, which is inferred to be Colorectal Carcinoma.

Visual Summary

The box plots illustrate the distribution of celltype proportions for four macrophage subsets – Mac (M2C), Mac (M2B), Mac (M2A), and Mac (M2D) – across "Adj_normal" and "Tumor" conditions. Statistically significant differences (p-value < 0.1, as per applied parameters) are observed for all four subsets:

• Mac (M2C): A significantly higher proportion of Mac (M2C) cells is observed in the "Tumor" condition compared to "Adj_normal" tissue (p=1.59e-08). The median proportion in tumors is notably elevated.
• Mac (M2B): Similarly, Mac (M2B) cells show a significantly increased proportion in "Tumor" tissue compared to "Adj_normal" (p=2.94e-06), with a clear shift towards higher median values in the tumor microenvironment.
• Mac (M2A): In contrast, Mac (M2A) cells exhibit a significantly *lower* proportion in the "Tumor" condition compared to "Adj_normal" (p=1.75e-05). The median proportion is substantially reduced in tumors.
• Mac (M2D): Mac (M2D) cells also show a *decreased* proportion in "Tumor" tissue relative to "Adj_normal" (p=0.06). While the p-value is higher than for other subsets, it still falls within the defined statistical significance cutoff, indicating a trend of reduction.

Biological Interpretation

Macrophages are highly plastic immune cells that adapt their phenotype and function in response to microenvironmental cues, playing critical roles in tumor progression. The observed shifts in macrophage subsets within the colorectal tumor microenvironment provide important insights into the immune landscape of Colorectal Carcinoma.

• Pro-Tumorigenic Macrophage Polarization (M2C and M2B enrichment): The significant increase in Mac (M2C) and Mac (M2B) populations within tumors is highly relevant.
• M2C macrophages are typically associated with immunosuppression, promoting tumor immune evasion and metastasis. They are known for their ability to produce high levels of IL-10 and TGF-$\beta$, which suppress T cell responses and support tumor growth PubMed search: M2C macrophages cancer immunosuppression.
• M2B macrophages exhibit a mixed phenotype, but often contribute to inflammation, angiogenesis, and matrix remodeling, which are all processes that support tumor development and progression PubMed search: M2B macrophages tumor angiogenesis.
• The enrichment of these particular M2-like subsets strongly suggests a re-programming of the macrophage compartment towards a pro-tumorigenic, immunosuppressive phenotype in colorectal tumors.
• Specific M2 Subtype Dynamics (M2A and M2D decrease): The decrease in Mac (M2A) and Mac (M2D) populations in tumors, despite M2 typically being associated with pro-tumor functions, highlights the complexity and heterogeneity of macrophage polarization.
• M2A macrophages are classically associated with Th2 responses, tissue repair, and parasite infections, often induced by IL-4 and IL-13 GeneCards: M2A macrophages. Their reduction in tumors might suggest a shift away from these specific "wound healing" M2 programs towards other pro-tumorigenic M2 subsets (M2B/C) that are more directly driven by tumor-derived factors or microenvironmental hypoxia/immunosuppression.
• M2D macrophages are sometimes referred to as tumor-associated macrophages (TAMs) induced by adenosine signaling, promoting angiogenesis and immune suppression PubMed search: M2D macrophages tumor associated. A decrease in Mac (M2D) as defined by this dataset's specific subset annotation, while other M2 subsets (M2B, M2C) increase, indicates that the overall TAM population within the colon tumor microenvironment is shifting its precise polarization state, rather than a uniform increase or decrease of all M2-like cells. It underscores that the broad "M2" categorization encompasses functionally distinct populations.

Overall, these findings indicate a significant remodeling of the macrophage landscape in Colorectal Carcinoma, characterized by a shift towards specific pro-tumorigenic (M2C, M2B) subsets, which likely contributes to immune evasion and tumor progression.

Clinical or Translational Implications

• Prognostic Biomarkers: The proportional shifts in specific macrophage subsets, particularly the increases in Mac (M2C) and Mac (M2B), could serve as valuable prognostic biomarkers for Colorectal Carcinoma. Higher proportions of these immunosuppressive and pro-angiogenic macrophage subsets might correlate with more aggressive disease or poorer patient outcomes.
• Therapeutic Targets: Understanding the precise macrophage polarization within the tumor microenvironment opens avenues for targeted immunotherapies. Strategies aiming to deplete pro-tumorigenic M2C/M2B macrophages, or to re-educate them towards an anti-tumor M1-like phenotype, could be effective in conjunction with existing treatments PubMed search: macrophage reprogramming cancer therapy.
• Immunosuppressive Microenvironment: The dominance of M2C and M2B cells suggests a highly immunosuppressive tumor microenvironment in Colorectal Carcinoma. This information is crucial for predicting response to immune checkpoint inhibitors or other immunotherapies, as these agents may be less effective in environments heavily skewed towards immunosuppressive macrophage populations. Combinatorial therapies targeting both checkpoint inhibition and macrophage polarization might be more beneficial.

11. Intestinal Epithelial Cell Ploidy Distribution in Colorectal Carcinoma

[Analysis Visualization Results]...

Analysis Overview

This analysis visualizes the ploidy status (Aneuploid, Diploid, and Unclear) of Intestinal Epithelial cells, the identified tumor-origin cell type, across individual samples from both "Adj_normal" and "Tumor" conditions. This provides a detailed, sample-specific view of genomic stability within these critical cell populations in the context of Colorectal Carcinoma.

Visual Summary

The stacked bar plots display the proportional distribution of aneuploid (dark red), diploid (light orange), and unclear (light green) Intestinal Epithelial cells for each sample.

• Adjacent Normal (Adj_normal) Samples: All "Adj_normal" samples show a highly consistent pattern, with Intestinal Epithelial cells being almost exclusively diploid. The light orange bar dominates each column, representing nearly 100% diploid cells. A negligible fraction of cells are categorized as "Unclear" (light green) and virtually no "Aneuploid" cells are observed in these normal samples.
• Tumor Samples: In stark contrast, Intestinal Epithelial cells from "Tumor" samples exhibit a dramatic shift in ploidy distribution. A significant and often dominant proportion of these cells are Aneuploid (dark red).
• The percentage of aneuploid cells varies considerably across individual tumor samples. For instance, some samples like "Tumor C166", "Tumor C161", "Tumor C150", and "Tumor C145" show the highest levels of aneuploidy, reaching approximately 90-95% of Intestinal Epithelial cells.
• Other tumor samples, such as "Tumor C104", "Tumor C106", and "Tumor C169", display lower but still substantial proportions of aneuploid cells, ranging from approximately 20% to 35%.
• The "Unclear" category remains a very minor component across most tumor samples, similar to the adjacent normal condition.

Biological Interpretation

The observed ploidy patterns strongly correlate with the biological state of the tissue and the inferred disease context of Colorectal Carcinoma.

1. Normal Tissue Homeostasis: In "Adj_normal" colon tissue, Intestinal Epithelial cells are predominantly diploid. This is the expected and healthy state for somatic cells, reflecting proper chromosome segregation during cell division and genomic stability.
2. Malignant Transformation and Aneuploidy: The Intestinal Epithelial cell population has been identified as the "Resolved tumor-origin cell type." The high prevalence of aneuploid cells in "Tumor" samples is a hallmark of cancer. Aneuploidy, an abnormal number of chromosomes, arises from genomic instability, which is a key driver of tumorigenesis and tumor evolution. This instability allows cancer cells to acquire advantageous mutations and adapt to selective pressures [1].
3. Tumor Heterogeneity: The variability in the proportion of aneuploid cells among different tumor samples highlights intratumoral and intertumoral heterogeneity. This can reflect different stages of tumor progression, varying degrees of genomic instability, or the presence of subclones with distinct ploidy profiles within a single tumor. The higher the fraction of aneuploid cells, generally the more advanced or aggressive the tumor.

Clinical or Translational Implications

The detection of aneuploid Intestinal Epithelial cells is highly significant for the diagnosis and potential management of Colorectal Carcinoma.

1. Diagnostic Marker: A high proportion of aneuploid Intestinal Epithelial cells in a biopsy sample serves as a strong indicator of malignancy and can help differentiate tumor tissue from normal or benign conditions.
2. Prognostic Relevance: The degree of aneuploidy can sometimes be correlated with tumor aggressiveness, clinical stage, and patient outcomes in colorectal cancer. Tumors with a higher burden of aneuploidy might be associated with more aggressive behavior and a poorer prognosis [2].
3. Therapeutic Strategies: Understanding the ploidy status can indirectly inform therapeutic approaches. Genomic instability and aneuploidy are often associated with dysfunctional DNA damage response pathways, which could represent vulnerabilities for targeted therapies in specific patients.

---

References:

[1] Hanahan, D., & Weinberg, R. A. (2011). Hallmarks of cancer: the next generation. Cell, 144(5), 646-674. PubMed Search: "Hallmarks of Cancer"

[2] Lengauer, C., Kinzler, K. W., & Vogelstein, B. (1998). Genetic instability in colorectal cancers. Nature, 396(6712), 643-649. PubMed Search: "aneuploidy colorectal cancer prognosis"

12. Cell-Cell Interaction Analysis in Colorectal Carcinoma Microenvironment

[Analysis Visualization Results]...

Analysis Overview

This analysis investigates cell-cell interaction (CCI) patterns using CellPhoneDB, comparing 'Tumor' tissue with 'Adj_normal' tissue from human colon samples. The focus is on interactions involving Intestinal Epithelial cells (the resolved tumor-origin cell type), Fibroblasts, Macrophages, and T cells (CD4+ and CD8+), which are key components of the tumor microenvironment (TME) and normal tissue. The results highlight differentially active ligand-receptor pairs and cellular communication networks that may drive disease progression or maintain tissue homeostasis.

Visual Summary

The dot plots illustrate cell-cell interactions, with dot size representing the negative log10 of the p-value (significance) and dot color indicating the log2 of the mean expression of the ligand-receptor pair. A maximum of 80 interactions per group are displayed, ordered by the tool's internal ranking criteria.

Cell-Cell Interactions in Adjacent Normal Tissue (Adj_normal)

• Limited Interactions: The 'Adj_normal' tissue exhibits a relatively sparse network of interactions compared to the 'Tumor' tissue.
• Key Cell Types: The dominant interactions occur among Diploid Intestinal Epithelial cells (self-interactions and with T CD8+ cells) and T cell CD4+ and T cell CD8+ (self-interactions).
• Prominent Ligand-Receptor Pairs: Interactions include CEACAM1, CEACAM5, CEACAM6, DSC2 (Desmocollin 2), EFNB1_EPHB2, APP_SORL1, PIGR (Polymeric Immunoglobulin Receptor), DHEAsulfate_bySULT2B_PPARA, ProstaglandinE2_byPTGES2_PTGER4 for Diploid Intestinal Epithelial cell self-interactions. LCK_CD8_receptor is noted for Diploid Intestinal Epi|T CD8+ interactions.
• Interaction Strength: While significant (larger dots), the mean expression values (colors) are generally lower compared to many interactions in the tumor, suggesting a basal level of communication.

Cell-Cell Interactions in Tumor Tissue (Tumor)

• Expanded Interaction Network: The 'Tumor' microenvironment shows a significantly more complex and extensive network of cell-cell interactions, involving a wider array of cell types and ligand-receptor pairs.
• Dominance of Aneuploid Intestinal Epithelial Cells: Aneuploid Intestinal Epithelial cells are highly active interactors, engaging in extensive self-interactions and robust communication with Macrophages, T CD4+, and T CD8+ cells. This aligns with the Aneuploid status (14.1% of cells) and Intestinal Epithelial cell being the Resolved tumor-origin cell type.
• Myeloid Cell Hub: Macrophages are central to many interactions, notably with Aneuploid Intestinal Epithelial cells and T CD8+ cells.

Key Ligand-Receptor Pairs Enriched in Tumor

• Adhesion/ECM Remodeling: CDH1_integrin, COL17A1_integrin, SPP1_integrin, NRG1_integrin, LAMA3_integrin, MMP2L1_MMP2L1. These suggest altered cell adhesion, increased invasiveness, and extracellular matrix (ECM) remodeling.
• Growth Factors/Cytokines: TGFB1_TGFBR1 (Transforming Growth Factor Beta 1 - TGF-beta receptor 1), BMP2_BMPR1A (Bone Morphogenetic Protein 2 - BMP receptor type 1A). TGF-beta signaling is a known driver of cancer progression and immunosuppression.
• Immune Modulation: CD80_CD28, CD86_CD28 (T cell co-stimulation), CEACAM5_CEACAM1, LILRB1_HLADRB1 (immune checkpoint), TNFSF4_TNFRSF4 (OX40-OX40L axis). These highlight active immune responses that could be either anti-tumor or pro-tumorigenic/immunosuppressive depending on context. APOE_TREM2 is also present, implicating lipid metabolism and myeloid cell function.
• EPH/Ephrin Signaling: Multiple pairs like EFNA3_EPHA1, EFNB1_EPHB2, EPHA2_EPHA4, EFNB2_EPHB4 are highly active, critical for cell migration and tissue patterning, often dysregulated in cancer.
• Increased Significance and Expression: Many interactions in the 'Tumor' plot show larger dot sizes (more significant p-values) and brighter colors (higher mean expression) compared to 'Adj_normal', indicating robust and biologically active signaling pathways.

Biological Interpretation

The significant increase in both the number and strength of cell-cell interactions in the tumor microenvironment points towards a highly dynamic and reprogrammed ecosystem that supports colorectal carcinoma (CRC) progression.

1. Tumor Cell-Intrinsic Signaling and Adhesion: The high number of Aneuploid Intestinal Epithelial cell self-interactions, particularly involving various integrin pairs (CDH1_integrin, COL17A1_integrin, SPP1_integrin, NRG1_integrin, LAMA3_integrin) and EPH/ephrin family members, indicates altered cell-cell and cell-ECM adhesion, potentially facilitating tumor growth, invasion, and metastatic potential. MMP2L1_MMP2L1 interaction suggests active matrix remodeling.

• Integrins are crucial for cell adhesion, migration, and survival, often co-opted by cancer cells for invasion and metastasis. SPP1 (Osteopontin) is a cytokine that promotes tumor growth, metastasis, and immune suppression by interacting with integrins. [GeneCards SPP1: GeneCards]
• Ephrin receptors and their ligands regulate cell adhesion, migration, and angiogenesis, and their dysregulation is frequently observed in cancer. [PubMed: PubMed Search]

2. Reprogrammed Immune Microenvironment:

• Macrophage-Mediated Interactions: Macrophages are major players, interacting extensively with Aneuploid Intestinal Epithelial cells and T CD8+ cells. Ligand-receptor pairs such as TGFB1_TGFBR1, SPP1_integrin, APOE_TREM2, and various EPH/ephrin interactions suggest a pro-tumorigenic and immunosuppressive role for tumor-associated macrophages (TAMs). TGF-beta signaling is a potent immunosuppressor in the TME, promoting regulatory T cells and inhibiting effector T cells. [GeneCards TGFB1: GeneCards] TREM2 on myeloid cells can influence their polarization and phagocytic activity.
• T Cell Modulation: The presence of CD80_CD28 and CD86_CD28 interactions, primarily involving Macrophages and T CD8+ cells, indicates antigen presentation and co-stimulation. However, in the context of abundant immunosuppressive signals (e.g., TGF-beta, SPP1), this might reflect an exhausted or dysfunctional T cell state rather than effective anti-tumor immunity. The LILRB1_HLADRB1 interaction on T CD8+ cells suggests potential immune checkpoint activation or modulation.
• CEACAM5_CEACAM1 interaction, notably involving Aneuploid Intestinal Epithelial cells and Macrophages, can contribute to immune evasion by tumor cells. CEACAM5 is a known tumor marker and plays roles in cell adhesion and immune regulation. [GeneCards CEACAM5: GeneCards]

3. Inflammation and Metabolic Reprogramming: ProstaglandinE2_byPTGES2_PTGER4 is observed in both normal and tumor, but its enhanced context in tumor, alongside DHEAsulfate_bySULT2B_PPARA, suggests active inflammatory processes and metabolic reprogramming within the TME, which are hallmarks of cancer.

Clinical or Translational Implications

The identified differential cell-cell interactions offer several avenues for potential clinical and translational impact in Colorectal Carcinoma:

1. Therapeutic Target Prioritization:

• TGF-beta Pathway: The prominent TGFB1_TGFBR1 interactions, particularly between Aneuploid Intestinal Epithelial cells and Macrophages, represent a strong candidate for therapeutic targeting. Inhibitors of TGF-beta signaling are under investigation in cancer to reverse immunosuppression and inhibit EMT.
• Integrin-SPP1 Axis: The frequent SPP1_integrin interactions suggest that targeting SPP1 or its cognate integrin receptors could disrupt tumor cell adhesion, migration, and pro-tumorigenic macrophage functions.
• EPH/Ephrin System: The widespread activation of EPH/ephrin interactions presents an opportunity to target tumor invasion, angiogenesis, and proliferation.
• CEACAMs: Given their presence and role in tumor cell interactions, CEACAMs (e.g., CEACAM5) could be explored as targets for antibody-drug conjugates (ADCs) or other targeted therapies.

2. Biomarker Discovery: The identified ligand-receptor pairs that are highly enriched in the tumor microenvironment could serve as potential biomarkers for CRC progression, therapeutic response, or patient stratification. For instance, expression levels or activity of specific integrins or CEACAMs could be correlated with disease severity.
3. Understanding Immunotherapy Resistance: The interplay between T cell co-stimulation (CD80/86-CD28) and immunosuppressive signals (TGFB1_TGFBR1, LILRB1_HLADRB1) in the tumor microenvironment provides crucial insights into mechanisms of immune evasion. Targeting these immunosuppressive pathways could enhance the efficacy of existing immunotherapies.
4. Experimental Validation: Key ligand-receptor pairs and cellular interactions identified in this analysis warrant further experimental validation using in vitro co-culture models, organoids, or in vivo animal models to confirm their functional significance in CRC pathophysiology and therapeutic response.

13. Condition-Specific Cell-Cell Interaction Patterns in Colorectal Carcinoma

[Analysis Visualization Results]...

Analysis Overview

This analysis investigates condition-specific cell-cell interaction (CCI) patterns using single-cell RNA sequencing data from Colon tissue, comparing Tumor samples with Adjacent Normal tissue. The focus is on interactions involving Intestinal Epithelial cells (identified as the tumor-origin cell type) and key immune and stromal cell populations (Macrophage, Dendritic cell, T cell CD4+, T cell CD8+, NK cell, B cell, Plasma cell, Mast cell, Fibroblast, Smooth muscle cell, Endothelial cell). The visualization highlights interactions that differ significantly between conditions across individual samples. Dot size represents the significance of the interaction (-log10(p-value)), and dot color represents the scaled interaction strength.

Visual Summary

The dot plot reveals distinct and complex cell-cell interaction landscapes between 'Adj_normal' and 'Tumor' conditions.

• Adjacent Normal (Adj_normal) Samples: The upper left panel, representing adjacent normal tissue, shows a relatively high density of interactions with varying strengths and significances. This suggests a diverse and active set of homeostatic cell-cell communications characteristic of healthy colon tissue. Many interactions appear consistently present across most adjacent normal samples.
• Tumor Samples: The lower right panel, representing tumor tissue, exhibits a more heterogeneous pattern. While some interactions are clearly diminished or absent compared to adjacent normal, a striking feature is the emergence or significant upregulation of specific interaction modules in a subset of tumor samples. These upregulated interactions often display strong significance (large dot size) and high strength (dark red color), particularly in samples towards the bottom of the 'Tumor' section. This heterogeneity underscores the diverse nature of the tumor microenvironment across different patients or tumor regions.

Key Differences between Conditions:

• A significant number of interactions involving Diploid Intestinal Epithelial cells (Ent.Epi (Dip)) with immune and stromal cells (e.g., T cells, Macrophages, Endothelial cells, Fibroblasts) are highly prominent and strong in tumor samples, often showing weaker or absent signals in adjacent normal tissue. This suggests a rewired communication network facilitating tumor growth, immune evasion, or metastasis.
• Interactions such as CXCL12-CXCR4, PPIA-BSG (CD147), and various integrin-mediated interactions (e.g., SPP1-integrin_aVb1 complex) show particularly strong and widespread signals in tumor samples.
• Several immune cell-to-immune cell interactions, including CCL3-CCR1/CCR5 between Macrophages and T cells, also appear highly active in tumor samples.
• Conversely, some interactions consistently observed in adjacent normal tissue, potentially representing homeostatic functions, appear less frequent or weaker in tumor samples.

Biological Interpretation

The observed shifts in cell-cell interactions within the tumor microenvironment of colorectal carcinoma point to crucial pathways involved in tumor progression, angiogenesis, and immune modulation.

1. CXCL12-CXCR4 Axis Activation: This interaction, observed between various cell pairs including Diploid Intestinal Epithelial cells (Ent.Epi (Dip)) and Endothelial cells, Fibroblasts, Macrophages, and T cells (CD4+, CD8+), is consistently strong in tumor samples.

• Signaling Pathways & Mechanisms: CXCL12 (Stromal Cell-Derived Factor 1) binding to its receptor CXCR4 activates G-protein coupled receptor (GPCR) signaling, leading to downstream activation of pathways such as MAPK, PI3K/Akt, and Rho-GTPases. This axis is critical for cell migration, proliferation, and survival.
• Role in Colorectal Carcinoma: In CRC, the CXCL12-CXCR4 axis promotes tumor cell growth, invasion, angiogenesis, and metastasis. It also plays a significant role in recruiting immune cells, including immunosuppressive cells like regulatory T cells (Tregs) and myeloid-derived suppressor cells (MDSCs), contributing to an immunosuppressive tumor microenvironment [1].

2. PPIA-BSG (CD147) Interactions: Strong interactions between PPIA (Cyclophilin A) and BSG (CD147/Basigin) are observed, particularly involving Diploid Intestinal Epithelial cells (Ent.Epi (Dip)) and immune cells (T CD4+, Plasma, B cell, Macrophage).

• Signaling Pathways & Mechanisms: CD147, a transmembrane glycoprotein, interacts with cyclophilins such as PPIA. This interaction activates signaling cascades that promote matrix metalloproteinase (MMP) production, leading to extracellular matrix degradation and facilitating tumor invasion and metastasis. It also stimulates angiogenesis and regulates cell metabolism and survival [2].
• Role in Colorectal Carcinoma: Upregulation of CD147 and its interaction with PPIA are frequently associated with aggressive phenotypes in CRC, contributing to tumor cell proliferation, drug resistance, and metastatic potential.

3. SPP1-Integrin Interactions: The SPP1-integrin_aVb1 complex interaction between Macrophages and Fibroblasts is notably strong in tumor samples. Other integrin-mediated interactions (e.g., FN1-integrin_a3b1 complex between Fibroblasts and Epithelial cells) also show prominent signals.

• Signaling Pathways & Mechanisms: Integrins are cell surface receptors that mediate cell-extracellular matrix (ECM) and cell-cell interactions, transducing mechanical and biochemical signals into the cell. SPP1 (Osteopontin) is an ECM protein and cytokine that binds to various integrins, notably αVβ1 and αVβ3. This binding activates intracellular pathways including FAK, Src, MAPK, and PI3K/Akt, influencing cell adhesion, migration, survival, and differentiation [3].
• Role in Colorectal Carcinoma: In CRC, SPP1 is often highly expressed by tumor-associated macrophages (TAMs) and tumor cells, promoting ECM remodeling, tumor cell invasion, and angiogenesis. It also contributes to an immunosuppressive microenvironment by affecting immune cell polarization and recruitment. Altered integrin signaling is a hallmark of cancer progression.

4. VSIR-HLA-E Interactions: The interaction involving VSIR on Plasma cells and HLA-E on Diploid Intestinal Epithelial cells (Ent.Epi (Dip)) appears stronger in several tumor samples.

• Signaling Pathways & Mechanisms: VSIR (V-domain Ig suppressor of T cell activation), also known as VISTA, is an immune checkpoint molecule primarily expressed on myeloid cells and T cells, acting as an inhibitory receptor. HLA-E presents peptides derived from other MHC class I molecules and can interact with various receptors on NK and T cells, modulating immune responses. While less canonical than other checkpoint interactions, VSIR-HLA-E could represent a novel mechanism of immune regulation, potentially inducing immune tolerance or suppression within the tumor microenvironment [4].
• Role in Colorectal Carcinoma: If this interaction contributes to immunosuppression, it would represent a mechanism by which tumor cells or associated plasma cells evade anti-tumor immunity.

5. CCL3-CCR1/CCR5 Chemokine Axis: Interactions between CCL3 from Macrophages and CCR1/CCR5 on T cells (CD4+, CD8+) are pronounced in tumor samples.

• Signaling Pathways & Mechanisms: CCL3 (MIP-1α) is a chemokine that attracts leukocytes bearing its receptors, CCR1 and CCR5. Binding activates GPCRs, initiating intracellular signaling that leads to chemotaxis and immune cell activation or differentiation.
• Role in Colorectal Carcinoma: In the CRC tumor microenvironment, this axis can mediate the recruitment of various immune cells. Depending on the context, this recruitment can contribute to tumor-promoting inflammation or an immunosuppressive milieu, for example, by recruiting specific subsets of macrophages or T cells that support tumor growth and immune evasion.

Clinical or Translational Implications

The identified differential cell-cell interactions in colorectal carcinoma offer several potential avenues for therapeutic intervention.

• Targeting the CXCL12-CXCR4 Axis: Given its widespread involvement in tumor progression, angiogenesis, and immune evasion in CRC, blocking CXCR4 or CXCL12 represents a promising therapeutic strategy.
• Therapeutic Agents: Plerixafor (a CXCR4 antagonist) is already FDA-approved for stem cell mobilization and is being investigated in various cancers, including CRC, to inhibit metastasis and enhance the efficacy of chemotherapy and immunotherapy. Other CXCR4 inhibitors are in development. PubMed search: CXCR4 inhibitor colorectal cancer
• Inhibiting PPIA-CD147 Interactions: The strong association of PPIA-CD147 with aggressive CRC phenotypes suggests that disrupting this axis could suppress multiple facets of tumor progression, including invasion and metastasis.
• Therapeutic Agents: Anti-CD147 monoclonal antibodies and small molecule inhibitors are currently in preclinical and early clinical development for various cancers, including those of gastrointestinal origin. GeneCards: BSG
• Modulating SPP1-Integrin Signaling: Targeting SPP1 or its integrin receptors could interfere with critical tumor-stromal interactions, thereby inhibiting ECM remodeling, tumor cell invasion, and the establishment of an immunosuppressive microenvironment.
• Therapeutic Agents: Neutralizing antibodies against SPP1 and small molecule integrin inhibitors (e.g., targeting αVβ1, αVβ3, or αVβ5 integrins) are under investigation as anti-cancer agents. PubMed search: Osteopontin integrin cancer therapy
• Novel Immune Checkpoint Blockade (VSIR): If the VSIR-HLA-E interaction is confirmed to contribute to immune suppression, targeting VSIR (VISTA) could represent a novel immune checkpoint blockade strategy to reactivate anti-tumor immune responses, potentially complementing existing therapies.
• Therapeutic Agents: Anti-VSIR (VISTA) antibodies are in preclinical and early clinical development as novel immune checkpoint inhibitors. PubMed search: VISTA immune checkpoint therapy
• Targeting Chemokine Receptors (CCR1/CCR5): Modulating the CCL3-CCR1/CCR5 axis could alter the composition and function of the immune infiltrate within the tumor microenvironment, potentially shifting it towards an anti-tumor phenotype.
• Therapeutic Agents: CCR1 and CCR5 antagonists are being explored in various inflammatory conditions and cancers to impact immune cell trafficking and function. GeneCards: CCR1

These findings underscore the complex interplay within the colorectal tumor microenvironment and highlight several critical communication pathways that warrant further investigation as potential therapeutic targets for personalized and combination therapies.

---

References:

[1] GeneCards: CXCL12. https://www.genecards.org/cgi-bin/carddisp.pl?gene=CXCL12

[2] GeneCards: BSG. https://www.genecards.org/cgi-bin/carddisp.pl?gene=BSG

[3] GeneCards: SPP1. https://www.genecards.org/cgi-bin/carddisp.pl?gene=SPP1

[4] PubMed search: VISTA immune checkpoint therapy. https://pubmed.ncbi.nlm.nih.gov/?term=VISTA+immune+checkpoint+therapy

14. Cell-Cell Interaction Analysis in Colorectal Carcinoma: Immune Checkpoint and Cell Cycle Pathways

[Analysis Visualization Results]...

Analysis Overview

This analysis investigates cell-cell interactions (CCI) involving specific immune checkpoint and cell cycle pathway genes within the colorectal tumor microenvironment, comparing them between 'Tumor' and 'Adj_normal' conditions. The focus is on interactions between Intestinal Epithelial cells, major immune cells (B cell, Dendritic cell, Macrophage, Mast cell, NK cell, Plasma cell, T cell CD4+, T cell CD8+), and stromal cells (Endothelial cell, Fibroblast, Smooth muscle cell). The results are presented as a dot plot, where each dot represents a specific ligand-receptor pair interaction between two cell types in a given sample. The size of the dot corresponds to the statistical significance (-log10(p-value)), and the color intensity reflects the scaled interaction strength, highlighting interactions that significantly differ between conditions.

Visual Summary

The dot plot displays a comprehensive landscape of cell-cell interactions across individual samples from both 'Adj_normal' and 'Tumor' conditions.

• Overall Pattern: There is a stark contrast in CCI activity between the two conditions. The 'Tumor' samples exhibit a significantly higher number and intensity of interactions compared to the 'Adj_normal' samples. This indicates a highly active and remodelled communication network within the colorectal tumor microenvironment.
• Adj_normal Condition: While some interactions are present in 'Adj_normal' tissue, they are generally less frequent, weaker, and less widespread across samples. Notable interactions include DHEAsulfate-PPARG and ProstaglandinE2-PTGERs between Intestinal Epithelial cells, suggesting homeostatic or inflammatory signaling in the healthy/adjacent tissue.
• Tumor Condition: The 'Tumor' condition is characterized by a dense and widespread pattern of strong interactions. Multiple distinct clusters of highly significant and robust interactions are prominent. These highly active interactions predominantly involve Intestinal Epithelial cells (both diploid and aneuploid), Macrophages, T cells (CD4+, CD8+), Endothelial cells, and Fibroblasts. This widespread activation underscores the complex interplay between tumor cells and their surrounding immune and stromal cells.

Key Interaction Categories:

• Immune Checkpoint Interactions: The interaction between CD274 (PD-L1) and PDCD1 (PD-1) is particularly prominent and strong in many tumor samples, involving both diploid and aneuploid Intestinal Epithelial cells interacting with CD8+ T cells. Other immune-modulatory interactions like LAGLS9-HAVCR2 (Galectin-9-TIM-3) are also visible.
• Growth Factor Signaling: Interactions involving EGFR ligands such as HBEGF, AREG, and TGFA with EGFR on Intestinal Epithelial cells (diploid and aneuploid), Macrophages, and Endothelial cells are highly active in the tumor.
• TGF-β Signaling: A very extensive and strong set of interactions involving TGFB1 with its receptors (TGFBR1, TGFBR2, TGFBR3) is observed across a wide range of cell types in the tumor, including Intestinal Epithelial cells, Macrophages, T cells, Endothelial cells, Fibroblasts, and Plasma cells. This highlights a pervasive role of TGF-β signaling in the tumor microenvironment.
• Integrin-Mediated Interactions: Numerous integrin-related interactions (e.g., FN1-integrin, integrin_avb6_complex) are highly active, often involving Intestinal Epithelial cells, Fibroblasts, and Macrophages, suggesting active cell-ECM and cell-cell adhesion and remodeling. Notably, the integrin_avb6_complex-TGFB1 interaction is strongly upregulated in tumor.
• Chemokine Signaling: Interactions such as CXCL12-CXCR4 between Fibroblasts and Endothelial cells also appear to be activated in the tumor.
• Ploidy Status: The analysis differentiates between diploid (Dip) and aneuploid (Aneup) Intestinal Epithelial cells in the interaction labels, showing that both participate in significant interactions within the tumor, but some pathways may be preferentially engaged by aneuploid (tumor) cells.

Biological Interpretation

The observed surge in specific cell-cell interactions within the tumor microenvironment provides critical insights into colorectal carcinoma progression, immune evasion, and stromal remodeling. The targeted gene list, which includes immune checkpoint and cell cycle pathway components, effectively captures key oncogenic and immune-modulatory pathways.

1. CD274 (PD-L1) - PDCD1 (PD-1) Interactions:

• Signaling Pathway/Mechanism: This critical immune checkpoint axis involves the binding of Programmed Death-Ligand 1 (PD-L1, encoded by *CD274*) on tumor cells (Intestinal Epithelial cells, both diploid and aneuploid) or other cells in the tumor microenvironment to Programmed Death-1 (PD-1, encoded by *PDCD1*) on T cells (specifically CD8+ T cells). This interaction delivers an inhibitory signal to T cells, leading to their anergy or exhaustion, thereby allowing tumor cells to evade anti-tumor immunity.
• Therapeutic Potential: Blocking the PD-1/PD-L1 interaction can restore T cell activity and enhance anti-tumor immune responses.
• Therapeutic Agents: Immune checkpoint inhibitors targeting PD-1 (e.g., Pembrolizumab, Nivolumab) or PD-L1 (e.g., Atezolizumab, Durvalumab, Avelumab) are FDA-approved for various cancers, including specific subsets of metastatic colorectal cancer, particularly those with high microsatellite instability (MSI-H) or mismatch repair deficiency (dMMR) https://pubmed.ncbi.nlm.nih.gov/36380486/.

2. TGFB1 - TGFBR1/2/3 Interactions:

• Signaling Pathway/Mechanism: Transforming Growth Factor Beta 1 (TGFB1) is a pleiotropic cytokine that binds to its receptor complex (comprising Type I, II, and sometimes III receptors: TGFBR1, TGFBR2, TGFBR3). In the context of advanced colorectal cancer, TGF-β signaling typically promotes tumor progression by driving epithelial-to-mesenchymal transition (EMT), enhancing angiogenesis, inducing immunosuppression (e.g., by promoting regulatory T cells and inhibiting effector T cells), and contributing to fibrosis in the tumor stroma. Signaling occurs via SMAD-dependent and SMAD-independent pathways.
• Therapeutic Potential: Inhibiting TGF-β signaling can counteract tumor-promoting effects and potentially enhance responses to other therapies by reversing immunosuppression and preventing metastasis.
• Therapeutic Agents: Several agents targeting the TGF-β pathway are under investigation, including small molecule inhibitors of TGFBR1 kinase (e.g., Galunisertib) and antibodies that neutralize TGF-β ligands (e.g., Fresolimumab) https://pubmed.ncbi.nlm.nih.gov/33130541/.

3. HBEGF/AREG/TGFA - EGFR Interactions:

• Signaling Pathway/Mechanism: Heparin-binding EGF-like growth factor (HBEGF), Amphiregulin (AREG), and Transforming Growth Factor Alpha (TGFA) are ligands that bind to and activate the Epidermal Growth Factor Receptor (EGFR). EGFR activation is a key driver of cell proliferation, survival, migration, and angiogenesis in many epithelial cancers, including colorectal cancer. Downstream signaling typically involves the RAS/MAPK, PI3K/AKT, and JAK/STAT pathways, which are critical for cell cycle progression and survival.
• Therapeutic Potential: Blocking EGFR activation can inhibit tumor growth and metastasis.
• Therapeutic Agents: Monoclonal antibodies targeting EGFR (e.g., Cetuximab, Panitumumab) are standard-of-care treatments for metastatic colorectal cancer in patients with wild-type RAS genes https://pubmed.ncbi.nlm.nih.gov/34215886/.

4. Integrin_avb6_complex - TGFB1 Interaction:

• Signaling Pathway/Mechanism: Integrin αvβ6, expressed primarily on epithelial cells, is a critical activator of latent TGF-β1, converting it into its biologically active form. This interaction creates a potent feed-forward loop where αvβ6-expressing tumor cells directly activate TGF-β, which then promotes EMT, invasion, immunosuppression, and fibrosis. The presence of this strong interaction, especially involving aneuploid Intestinal Epithelial cells and Macrophages, highlights its importance in the tumor context.
• Therapeutic Potential: Inhibiting this specific integrin or its interaction with TGF-β could disrupt a crucial tumor-promoting axis and potentially sensitize tumors to other therapies.
• Therapeutic Agents: While pan-integrin inhibitors like Cilengitide have been explored, more specific αvβ6 blocking antibodies are under development for various fibrotic diseases and cancers, aiming to directly interrupt this activation pathway https://pubmed.ncbi.nlm.nih.gov/30679803/.

5. CXCL12 - CXCR4 Interaction:

• Signaling Pathway/Mechanism: The chemokine CXCL12 (stromal cell-derived factor 1) binding to its receptor CXCR4 activates G-protein coupled receptor signaling pathways. This axis is well-known to promote tumor cell growth, survival, angiogenesis, and metastasis. It also plays a significant role in orchestrating the trafficking of immune cells within the tumor microenvironment, potentially recruiting immunosuppressive cell types.
• Therapeutic Potential: Targeting the CXCL12-CXCR4 axis can disrupt tumor progression, metastasis, and potentially modulate the immune landscape.
• Therapeutic Agents: Plerixafor, a CXCR4 antagonist, is approved for hematopoietic stem cell mobilization and is being investigated in oncology to enhance anti-cancer therapies by mobilizing tumor-infiltrating immune cells or sensitizing tumor cells https://pubmed.ncbi.nlm.nih.gov/34526372/.

Clinical or Translational Implications

The robust cell-cell interaction patterns observed in colorectal carcinoma underscore the complexity of the tumor microenvironment and provide actionable insights for therapeutic development.

• Established Targets: The strong activation of the PD-1/PD-L1 axis and EGFR signaling in tumor samples reinforces their established roles as therapeutic targets in colorectal cancer. The widespread nature of these interactions, involving both diploid and aneuploid epithelial cells, suggests their broad relevance across the tumor cell population.
• Emerging Therapeutic Strategies: The prominence of TGF-β signaling and the Integrin αvβ6-TGFB1 activation axis highlights their potential as targets to overcome resistance to existing therapies, modulate the immunosuppressive microenvironment, and inhibit metastasis. Combining inhibitors of these pathways with current standards of care (e.g., chemotherapy, anti-EGFR therapies, or PD-1/PD-L1 blockers) could represent a promising strategy to improve patient outcomes.
• Microenvironment-Focused Therapies: The extensive network of interactions involving stromal (fibroblasts, endothelial cells) and immune cells (macrophages, T cells) emphasizes that effective therapies must consider not only the tumor cells themselves but also their dynamic interplay with the surrounding microenvironment. Modulating the CXCL12-CXCR4 axis, for instance, could impact both tumor cell behavior and immune cell infiltration.
• Biomarker Development: The identification of specific and strong CCIs unique to the tumor microenvironment could lead to the development of novel biomarkers for patient stratification, predicting response to targeted therapies, or monitoring disease progression. For instance, the expression levels of interacting partners or the activity of specific pathways could be assessed.
• Personalized Medicine: Understanding the specific repertoire of CCIs in individual patient tumors could guide personalized treatment approaches, allowing clinicians to select therapies that best target the most active and critical communication pathways in a patient's unique tumor microenvironment.

15. Intestinal Epithelial Cell Surfaceome Marker Expression in Colorectal Carcinoma

[Analysis Visualization Results]...

Analysis Overview

This analysis presents a dot plot visualization of surfaceome marker gene expression specifically within Intestinal Epithelial cells, comparing Adj_normal, Diploid Tumor, and Tumor conditions from Colon tissue samples. The plot aims to identify differentially expressed surface markers that could serve as diagnostic biomarkers or therapeutic targets in Colorectal Carcinoma (CRC). Markers were selected based on high expression and prevalence within each condition, focusing on surfaceome genes to prioritize druggable targets.

Visual Summary

The dot plot displays the mean expression (color intensity) and the fraction of cells expressing a gene (dot size) for selected surfaceome markers across individual samples categorized by condition (Adj_normal, Diploid Tumor, Tumor).

• Condition-specific Clustering: Samples clearly cluster by condition. The "Adj_normal" samples exhibit a distinct expression profile, primarily driven by a set of markers that are largely absent or expressed at very low levels in tumor samples. The "Tumor" samples form a robust cluster showing high expression of a different set of markers. "Diploid Tumor" samples appear to be largely similar to "Adj_normal" in terms of marker expression for the displayed markers, suggesting that the primary changes in surfaceome expression are associated with aneuploidy or other tumor-specific alterations rather than simply being derived from a tumor microenvironment, or that these diploid tumor cells are not the actual tumor cells (i.e., they are part of the normal epithelium adjacent to or within the tumor, or stromal cells misclassified as Intestinal Epithelial cells if the ploidy labels were derived only from epithelial cells). Given the "Resolved tumor-origin cell type: Intestinal Epithelial cell", it's more likely that the 'Diploid Tumor' group represents non-cancerous epithelial cells within the tumor microenvironment that haven't acquired full neoplastic changes or are adjacent normal cells collected within the tumor region.
• Distinct Tumor Signatures: The "Tumor" condition samples (lower panel) show uniformly high expression (dark, large dots) of a cluster of genes including *PIGR*, *ITM2C*, *VSIG2*, *SLC26A2*, *CDH5*, *CD164*, *ATP1A1*, *TMEM123*, *HLA-E*, *CD151*, *LMAN2*, *SYPL1*, *APP*, *TMEM219*, *CD46*, *ATP1B3*, *ITGB1*, *SLC12A2*, *PLPP2*, *LAMP1*, *ATRAID*, *CEACAM5*, *DSG2*, *TSPAN3*, *APLP2*, *RPLP1*, *SSR1*, *SSK1*, *TM9SF2*, *HLM3*, *EBP*, *CEACAM6*, *PIGT*, *BACE2*, *CD44*, *CD320*, *SERINC2*, *LRP6*, *FCRTG*, *SLC44A1*, *GPRC5A*, *SERINC3*, *TGOLN2*, *PITTG1P*, *CHPT1*, *PRSS8*, *SLCT3B*, *SDC1*, *GPR160*, *SLC52A2*, and *MPZL1*.
• Loss of Normal Epithelial Markers in Tumor: Conversely, markers like *AQP3*, *CA12*, *SLC39A5*, *ATP1A1*, *TMEM123*, *SPP1*, *CD151*, *LMAN2*, *SYPL1*, *APP*, and *TMEM219* are highly expressed in "Adj_normal" samples but are markedly downregulated or absent in the "Tumor" samples.

Biological Interpretation

The differential expression of surfaceome markers in Intestinal Epithelial cells between normal and tumor tissues reflects fundamental biological changes occurring during colorectal carcinogenesis. The identified tumor-enriched markers often play roles in cell proliferation, survival, adhesion, invasion, and immune evasion, consistent with the aggressive phenotype of cancer cells. The high expression of these markers suggests their potential involvement in driving tumor progression and offers avenues for targeted therapies.

We highlight key tumor-upregulated surfaceome markers with their biological roles and potential as therapeutic targets:

• CEACAM5 (Carcinoembryonic Antigen-related Cell Adhesion Molecule 5)
• Description: CEACAM5 is a glycosylphosphatidylinositol (GPI)-anchored cell surface glycoprotein involved in cell adhesion, signal transduction, and modulation of the immune response. It is a well-established tumor marker.
• Pathways/Mechanisms: CEACAM5 can promote cell growth and survival by activating various signaling pathways, including the MAPK and PI3K/Akt pathways, and can inhibit anoikis. It also functions in cell-cell adhesion and tissue organization.
• Relevance in CRC: CEACAM5 is highly overexpressed in a majority of colorectal cancers and is widely used as a diagnostic and prognostic biomarker. Its high expression in tumor cells promotes metastatic potential and resistance to chemotherapy GeneCards: CEACAM5.

Therapeutic Agents/Evidence:

• Established Target: Monoclonal antibodies targeting CEACAM5, such as *onvansertib* (a PLK1 inhibitor which has been explored in combination with anti-CEACAM5 strategies) or antibody-drug conjugates (ADCs) like *tusamitamab ravtansine*, are under investigation or in clinical trials for various cancers, including CRC PubMed Search: CEACAM5 antibody drug conjugate colorectal cancer. These agents aim to specifically deliver cytotoxic payloads to CEACAM5-expressing tumor cells.

CD47 (Cluster of Differentiation 47)

• Description: CD47 is a widely expressed transmembrane glycoprotein that acts as a "don't eat me" signal to macrophages by binding to SIRPα (Signal Regulatory Protein Alpha).
• Pathways/Mechanisms: Engagement of CD47 with SIRPα on myeloid cells (e.g., macrophages) inhibits phagocytosis, thus allowing cancer cells to evade immune surveillance. It can also modulate cellular proliferation and apoptosis, and is involved in cell adhesion and migration UniProt: CD47.
• Relevance in CRC: Overexpression of CD47 is frequently observed in various cancers, including CRC, and is associated with poor prognosis and increased metastatic potential. It contributes to immune escape by protecting cancer cells from phagocytic clearance PubMed Search: CD47 colorectal cancer immune evasion.

Therapeutic Agents/Evidence:

• Emerging Therapeutic Target: Anti-CD47 antibodies (e.g., *magrolimab*) are being developed to block the CD47-SIRPα interaction, thereby promoting phagocytosis of tumor cells by macrophages. These agents show promise in clinical trials for various hematological and solid tumors, including CRC PubMed Search: CD47 inhibitor colorectal cancer.

EPCAM (Epithelial Cell Adhesion Molecule)

• Description: EPCAM is a transmembrane glycoprotein involved in cell adhesion, proliferation, and differentiation. It is highly expressed in epithelial cells and often aberrantly expressed in carcinomas.
• Pathways/Mechanisms: EPCAM mediates homotypic intercellular adhesion and can also regulate cell signaling, including Wnt pathway components, impacting cell growth and survival. Its shedding can release an intracellular domain that functions as a transcription co-activator GeneCards: EPCAM.
• Relevance in CRC: EPCAM is a common marker for epithelial-derived tumors, including CRC, and its overexpression is often linked to increased tumor proliferation, invasiveness, and metastasis. It is also used for isolating circulating tumor cells.

Therapeutic Agents/Evidence:

• Established Target: *Catumaxomab*, a trifunctional antibody targeting EPCAM and CD3, was approved in Europe for malignant ascites (though later withdrawn from market for commercial reasons). Other EPCAM-targeting antibodies and CAR-T cell therapies are under investigation for solid tumors including CRC PubMed Search: EPCAM antibody colorectal cancer.

LRP6 (LDL Receptor Related Protein 6)

• Description: LRP6 is a transmembrane co-receptor for Wnt ligands, playing a crucial role in activating the canonical Wnt/β-catenin signaling pathway.
• Pathways/Mechanisms: Upon Wnt ligand binding, LRP6 undergoes phosphorylation and recruits Dishevelled (DVL) and Axin, leading to the stabilization and nuclear translocation of β-catenin, which activates target gene transcription involved in cell proliferation and differentiation UniProt: LRP6.
• Relevance in CRC: The Wnt/β-catenin pathway is aberrantly activated in the vast majority of CRC cases, often due to mutations in APC or β-catenin itself. Upregulation of LRP6 can further enhance Wnt signaling, contributing to tumor growth and progression in CRC PubMed Search: LRP6 colorectal cancer Wnt signaling.

Therapeutic Agents/Evidence:

• Potential Therapeutic Target: While LRP6 itself is not a direct drug target in the same way as cell surface receptors, its involvement in Wnt signaling makes it an attractive node for intervention. Inhibitors of Wnt/β-catenin pathway components, including compounds targeting LRP6 or its phosphorylation, are being explored. Targeting LRP6 could sensitize CRC cells to other therapies or reduce tumor growth PubMed Search: Wnt pathway inhibitors colorectal cancer.

SDC1 (Syndecan-1)

• Description: Syndecan-1 is a transmembrane heparan sulfate proteoglycan found on the surface of many cell types, especially epithelial cells.
• Pathways/Mechanisms: SDC1 interacts with numerous growth factors, chemokines, and extracellular matrix components, modulating their signaling. It is involved in cell adhesion, migration, proliferation, and angiogenesis by regulating pathways like MAPK and PI3K/Akt GeneCards: SDC1.
• Relevance in CRC: SDC1 expression is often altered in cancer; it can be lost from the surface of tumor cells but also highly expressed and shed into the tumor microenvironment, where it can promote tumor growth, invasion, and angiogenesis in CRC PubMed Search: Syndecan-1 colorectal cancer metastasis.

Therapeutic Agents/Evidence:

• Potential Therapeutic Target: Targeting SDC1 directly or indirectly (e.g., via its shedding enzymes or signaling partners) represents a potential strategy. Anti-SDC1 antibodies or small molecules disrupting SDC1 interactions could impact tumor progression. High circulating SDC1 levels also serve as a prognostic biomarker.

Clinical or Translational Implications

The identified surfaceome markers in Intestinal Epithelial cells hold significant clinical and translational potential for Colorectal Carcinoma:

• Biomarker Development: Markers like CEACAM5, EPCAM, and SDC1, which show strong and widespread upregulation in tumor cells, could be leveraged as diagnostic or prognostic biomarkers. These could be detected in tissue biopsies or potentially in liquid biopsies (e.g., circulating tumor DNA or exosomes) to monitor disease progression or recurrence.
• Therapeutic Target Identification: The analysis highlights several promising surfaceome proteins that are differentially expressed in tumor cells.
• Established Targets: CEACAM5 and EPCAM are already recognized targets, with ongoing clinical development of antibody-drug conjugates or other targeted therapies. The observed high expression in CRC Intestinal Epithelial cells reinforces their utility for such approaches.
• Emerging Targets: CD47, LRP6, and SDC1 represent emerging or potential therapeutic targets. CD47 inhibitors are particularly exciting due to their role in immune evasion and their potential to reactivate anti-tumor immune responses. Strategies to inhibit LRP6 or SDC1 could disrupt key signaling pathways driving CRC growth and metastasis.
• Patient Stratification and Personalized Medicine: Understanding the expression profiles of these markers could enable more precise patient stratification. For example, patients with high expression of specific markers might be more responsive to therapies targeting those proteins, moving towards a personalized medicine approach in CRC treatment.
• Experimental Validation: The findings warrant further experimental validation to confirm the functional roles of these markers in CRC progression and to evaluate the efficacy of targeted therapies in preclinical models, and subsequently in clinical trials. This would involve *in vitro* studies (e.g., gene knockdown/overexpression in CRC cell lines) and *in vivo* models (e.g., patient-derived xenografts).

16. Macrophage Condition-Specific Surfaceome Markers in Colorectal Carcinoma

[Analysis Visualization Results]...

Analysis Overview

This analysis investigates the expression of surfaceome markers in macrophages, comparing those found in colorectal "Tumor" tissue with those from "Adj_normal" tissue. Utilizing a one-vs-rest comparison, the objective is to identify cell surface proteins that are differentially expressed, thereby providing insights into the functional state of macrophages in the tumor microenvironment (TME) and potentially pinpointing novel therapeutic targets for Colorectal Carcinoma.

Visual Summary

The dot plot visualizes the expression of various surfaceome markers across individual samples, categorized by their origin: "Adj_normal" or "Tumor" tissue.

• Distinct Phenotypic Shift: There is a clear and dramatic difference in the surfaceome profiles of macrophages between the two conditions. Macrophages residing within "Tumor" samples exhibit a significantly broader and higher expression of numerous surface markers compared to their counterparts in "Adj_normal" tissue.
• Adj_normal Macrophage Markers: In "Adj_normal" samples, markers such as *SLC40A1*, *CD36*, *PLAUR*, *SLC2A3*, *ITGB1*, *CD83*, *SIRPA*, and *ATP1A1* show moderate to high mean expression (darker red dots) and prevalence (larger dot size). *SLC40A1* and *CD36* appear particularly prominent in most "Adj_normal" samples.
• Tumor-Associated Macrophage (TAM) Markers: In stark contrast, macrophages from "Tumor" samples display strong and widespread upregulation of a large panel of markers. These include, but are not limited to, *SPP1*, *SCARB2*, *ICAM1*, *ATP13A3*, *HM13*, *TCIRG1*, *HAVCR2*, *HBEGF*, *TLR2*, *CD84*, *ITGAX*, *ADAM10*, *MMP14*, *ADAM9*, *TREM1*, *OLR1*, *CD58*, *FCGR1A*, *NRP1*, *ENG*, *NECTIN2*, *IL2RG*, *IL7R*, and *ALCAM*. For many of these, the dots are consistently large and dark red across a high percentage of "Tumor" samples, indicating both a high fraction of expressing cells and elevated mean expression levels. This pattern is indicative of a highly activated and phenotypically distinct macrophage population within the tumor.

Biological Interpretation

The observed gene expression patterns underscore the significant functional reprogramming of macrophages in the colorectal cancer TME, often referred to as Tumor-Associated Macrophages (TAMs).

• Pro-Tumoral Phenotype of TAMs: The extensive upregulation of surface markers in "Tumor" macrophages strongly suggests a predominant M2-like or immunosuppressive and pro-tumoral phenotype. TAMs are well-established orchestrators of cancer progression, contributing to angiogenesis, immune evasion, extracellular matrix remodeling, and metastasis in various cancers, including colorectal carcinoma. The diverse array of expressed receptors highlights their active involvement in complex cell-cell and cell-matrix interactions within the TME.
• Homeostatic Role of Adj_normal Macrophages: The markers found in "Adj_normal" macrophages, such as *SLC40A1* (iron export) and *CD36* (lipid uptake), likely reflect their roles in maintaining tissue homeostasis, nutrient sensing, and basal immune surveillance in healthy colon tissue. The relatively lower expression of many "Tumor"-associated markers in this population emphasizes their distinct, non-tumorigenic functional state.
• Functional Implications in CRC: The collective profile of highly expressed markers in TAMs points towards their critical roles in:
• Immune Suppression: Actively dampening anti-tumor immune responses, potentially fostering an environment conducive to tumor growth.
• Angiogenesis: Promoting the formation of new blood vessels that sustain tumor growth.
• Metastasis: Facilitating the invasion and dissemination of cancer cells by remodeling the local tissue environment.
• Growth and Survival: Providing signals that support tumor cell proliferation and survival.

Clinical or Translational Implications

The distinctive surfaceome signature of macrophages in the colorectal cancer TME provides a rich landscape for identifying and developing targeted therapeutic strategies. Markers highly expressed on TAMs represent promising candidates for selective targeting, depletion, or functional reprogramming to revert their pro-tumoral roles.

Key Markers in Tumor-Associated Macrophages (TAMs):

1. SPP1 (Osteopontin)

• Associated Signaling Pathways: Integrin-mediated signaling (e.g., through CD44, ITGB1, ITGAX), PI3K/Akt, and Wnt/β-catenin pathways.
• Role in TME (Macrophage context): SPP1 is a matricellular protein that promotes M2 macrophage polarization, enhances angiogenesis, and facilitates tumor cell migration, invasion, and immune evasion. It acts as a bridge between cells and the extracellular matrix.
• Potential as Therapeutic Target: Highly expressed by TAMs and often associated with poor prognosis in CRC, SPP1 presents an attractive target. Blocking SPP1 or its receptors could disrupt critical pro-tumoral pathways and limit TAM-mediated functions.
• Relevant Therapeutic Agents/Strategies: Investigational anti-SPP1 antibodies, integrin inhibitors. GeneCards: SPP1

2. ICAM1 (CD54)

• Associated Signaling Pathways: LFA-1 (CD11a/CD18) binding, NF-κB activation.
• Role in TME (Macrophage context): ICAM1 mediates cell-cell adhesion, influencing immune cell infiltration, antigen presentation, and interactions between TAMs, tumor cells, and endothelial cells. Its upregulation in TAMs can contribute to tumor progression and metastasis.
• Potential as Therapeutic Target: Modulating ICAM1 interactions could impact immune cell trafficking and the adhesive properties vital for tumor spread.
• Relevant Therapeutic Agents/Strategies: While broadly expressed, targeting ICAM1 might be explored in combination therapies to specific contexts. GeneCards: ICAM1

3. HBEGF (Heparin-binding EGF-like growth factor)

• Associated Signaling Pathways: EGFR activation (MAPK/ERK, PI3K/Akt pathways).
• Role in TME (Macrophage context): HBEGF, a potent mitogen and chemotactic factor, is secreted by TAMs to promote proliferation, survival, and migration of tumor cells and angiogenesis by acting on endothelial cells.
• Potential as Therapeutic Target: Targeting HBEGF or its receptor (EGFR) on TAMs could disrupt crucial growth and survival signals within the TME.
• Relevant Therapeutic Agents/Strategies: EGFR inhibitors (e.g., cetuximab, panitumumab currently used in CRC), anti-HBEGF antibodies. GeneCards: HBEGF

4. TLR2 (Toll-like Receptor 2)

• Associated Signaling Pathways: MyD88-dependent signaling, NF-κB activation, inflammatory cytokine production.
• Role in TME (Macrophage context): TLR2 on TAMs can be activated by microbial products or endogenous danger signals, leading to either pro-inflammatory or pro-tumoral responses. In CRC, TLR2 activation in TAMs often contributes to an immunosuppressive environment and tumor progression.
• Potential as Therapeutic Target: Inhibiting TLR2 signaling in TAMs could re-educate them towards an anti-tumor phenotype and reduce pro-tumoral inflammation.
• Relevant Therapeutic Agents/Strategies: TLR2 antagonists/inhibitors are under investigation. GeneCards: TLR2

5. MMP14 (Matrix Metalloproteinase 14, MT1-MMP)

• Associated Signaling Pathways: Extracellular matrix (ECM) degradation, activation of latent growth factors.
• Role in TME (Macrophage context): MMP14 is a membrane-bound metalloproteinase crucial for degrading ECM components, thereby facilitating tumor cell invasion, angiogenesis, and metastasis. TAMs are a significant source of MMPs.
• Potential as Therapeutic Target: Targeting MMP14 on TAMs could impede ECM remodeling, thus hindering tumor invasion and metastasis.
• Relevant Therapeutic Agents/Strategies: Specific MMP14 inhibitors are being developed due to challenges with broad-spectrum MMP inhibitors. GeneCards: MMP14

6. ADAM9 (ADAM Metallopeptidase Domain 9)

• Associated Signaling Pathways: Cell adhesion, ECM degradation, shedding of cell surface proteins (e.g., growth factors).
• Role in TME (Macrophage context): ADAM9 is a metalloprotease involved in cell adhesion, migration, and the shedding of various surface proteins, including those involved in growth factor signaling. Its expression in TAMs can contribute to ECM remodeling and altered signaling that promotes tumor progression.
• Potential as Therapeutic Target: Inhibiting ADAM9 could disrupt tumor invasion, angiogenesis, and pro-tumoral signaling networks.
• Relevant Therapeutic Agents/Strategies: ADAM inhibitors under research. GeneCards: ADAM9

7. TREM1 (Triggering Receptor Expressed on Myeloid cells 1)

• Associated Signaling Pathways: DAP12 signaling, NF-κB, MAPK/ERK. Amplifies TLR and NLR signaling.
• Role in TME (Macrophage context): TREM1 is an activating receptor that amplifies inflammatory responses. In the context of cancer, TREM1 on TAMs is often associated with pro-tumoral inflammation, promoting angiogenesis, tumor growth, and metastasis.
• Potential as Therapeutic Target: Blocking TREM1 could dampen pro-tumoral inflammatory signals and shift TAMs towards an anti-tumor phenotype.
• Relevant Therapeutic Agents/Strategies: Anti-TREM1 antibodies, TREM1 inhibitors (e.g., LP17). GeneCards: TREM1

8. FCGR1A (CD64, Fc-gamma Receptor Ia)

• Associated Signaling Pathways: FcR signaling, antibody-dependent cellular cytotoxicity (ADCC), phagocytosis.
• Role in TME (Macrophage context): FCGR1A is a high-affinity receptor for IgG, often found on activated macrophages. Its upregulation in TAMs indicates an activated state and potential involvement in antibody-dependent phagocytosis (ADCP) or ADCC, but also potentially in immune complex-mediated immune suppression.
• Potential as Therapeutic Target: Enhanced FCGR1A expression on TAMs could be leveraged for targeted drug delivery (e.g., antibody-drug conjugates) to activated macrophages within the TME, or for therapeutic macrophage reprogramming.
• Relevant Therapeutic Agents/Strategies: Therapeutic antibodies, ADCs targeting FCGR1A. GeneCards: FCGR1A

9. NRP1 (Neuropilin 1)

• Associated Signaling Pathways: VEGF-A, Semaphorin 3A (SEMA3A) signaling, TGF-β signaling.
• Role in TME (Macrophage context): NRP1 acts as a co-receptor for VEGF-A and Semaphorin 3A. In TAMs, it contributes to angiogenesis by mediating VEGF signaling and influences immune cell migration and differentiation, fostering an immunosuppressive and pro-angiogenic phenotype.
• Potential as Therapeutic Target: Targeting NRP1 could disrupt critical angiogenesis and immune evasion pathways mediated by TAMs.
• Relevant Therapeutic Agents/Strategies: Anti-NRP1 antibodies, small molecule inhibitors of NRP1 interactions. GeneCards: NRP1

10. ENG (CD105, Endoglin)

• Associated Signaling Pathways: TGF-β superfamily signaling (co-receptor with TGF-β receptors), angiogenesis.
• Role in TME (Macrophage context): While prominently known on endothelial cells for angiogenesis, ENG expression on TAMs suggests their active participation in fostering angiogenesis and modulating TGF-β-mediated immunosuppression and pro-fibrotic responses within the TME.
• Potential as Therapeutic Target: Targeting ENG on TAMs could specifically inhibit their contribution to angiogenesis and modulate TGF-β-mediated immune suppression.
• Relevant Therapeutic Agents/Strategies: Anti-Endoglin antibodies (e.g., TRC105). GeneCards: ENG

11. ALCAM (CD166, Activated Leukocyte Cell Adhesion Molecule)

• Associated Signaling Pathways: CD6 signaling, cell adhesion.
• Role in TME (Macrophage context): ALCAM is involved in cell-cell adhesion. On TAMs, it may mediate interactions with tumor cells or other stromal components, influencing cell migration, immune surveillance, and potentially contributing to tumor progression and metastasis.
• Potential as Therapeutic Target: Disrupting ALCAM interactions could impact tumor cell metastasis and immune cell trafficking in the TME.
• Relevant Therapeutic Agents/Strategies: Investigational antibodies targeting ALCAM. GeneCards: ALCAM

Key Markers in Adjacent Normal Macrophages (for context):

1. SLC40A1 (Ferroportin, FPN1)

• Associated Signaling Pathways: Iron homeostasis.
• Role in TME (Macrophage context): SLC40A1 is the sole known iron exporter in mammals. Its expression in "Adj_normal" macrophages highlights their role in maintaining iron balance. Decreased expression in tumor macrophages might reflect altered iron metabolism within the TME, contributing to iron accumulation that can foster tumor growth.
• Potential as Therapeutic Target: While not a direct pro-tumoral target, manipulating iron metabolism via SLC40A1 could be an indirect strategy to induce ferroptosis in tumor cells or alter TAM function.
• Relevant Therapeutic Agents/Strategies: Iron chelators, ferroptosis-inducing agents. GeneCards: SLC40A1

2. SIRPA (CD172a, Signal-regulatory protein alpha)

• Associated Signaling Pathways: Integrin-associated signaling, phagocytosis regulation. Ligand is CD47.
• Role in TME (Macrophage context): SIRPA is an inhibitory receptor on myeloid cells. Its interaction with CD47 (expressed on many tumor cells) delivers a "don't eat me" signal, preventing macrophage-mediated phagocytosis. Its presence on "Adj_normal" macrophages helps maintain immune homeostasis and prevents auto-phagocytosis of healthy cells. Its relatively lower expression or different context in tumor macrophages, although still present, is relevant for understanding tumor immune evasion.
• Potential as Therapeutic Target: The CD47-SIRPA axis is a critical immune checkpoint. Targeting CD47 (on tumor cells) or SIRPA (on macrophages) to disrupt this interaction aims to unleash macrophage-mediated phagocytosis of tumor cells.
• Relevant Therapeutic Agents/Strategies: Anti-CD47 antibodies (e.g., magrolimab), anti-SIRPA antibodies. PubMed search: CD47 SIRPA cancer therapy

The profound differences in surface marker expression between normal and tumor-associated macrophages in colorectal carcinoma underscore the plasticity and critical role of TAMs in tumor progression. These identified markers represent valuable candidates for the development of targeted immunotherapies aiming to re-educate or deplete pro-tumoral macrophages, thereby enhancing anti-tumor immunity and improving patient outcomes. Further validation through functional studies and preclinical models will be crucial to translate these findings into effective clinical strategies.

17. Fibroblast Condition-Specific Surfaceome Marker Analysis in Colorectal Carcinoma

[Analysis Visualization Results]...

Analysis Overview

This analysis identifies condition-specific surfaceome markers in Fibroblast cells from single-cell RNA-seq data, comparing "Tumor" tissue with "Adj_normal" tissue in the context of Colorectal Carcinoma. The objective is to highlight differences in cell surface protein expression that might shed light on the altered functions of fibroblasts in the tumor microenvironment (TME) and identify potential therapeutic targets. The dot plot visualizes the mean expression level (color intensity) and the fraction of cells expressing each marker (dot size) across different patient samples grouped by condition. Only surfaceome markers with significant differential expression (based on nz_pct_score and nz_pct_FC cutoffs) were included.

Visual Summary

The dot plot clearly differentiates two main clusters of surface markers corresponding to the "Adj_normal" and "Tumor" conditions.

1. Adj_normal Fibroblast Markers: A distinct set of markers is highly expressed and prevalent in fibroblasts from adjacent normal tissue samples (top block, 'Adj_normal' rows). These markers show high mean expression (dark red) and are present in a large fraction of cells (large dots) within the normal samples, while being largely absent or lowly expressed in tumor fibroblasts.
2. Tumor Fibroblast Markers: Conversely, a large panel of surface markers exhibits high expression and prevalence specifically in fibroblasts from tumor tissue samples (bottom block, 'Tumor' rows). These markers are characterized by dark red, large dots in the tumor condition, indicating strong and widespread expression, and are minimally or not expressed in adjacent normal fibroblasts. This distinct expression profile strongly suggests a phenotypic shift in fibroblasts within the tumor microenvironment, indicating their activation into Cancer-Associated Fibroblasts (CAFs).
3. Heterogeneity within Conditions: While clear condition-specific patterns emerge, some heterogeneity is visible within samples of the same condition, particularly for tumor fibroblasts, where certain markers show varied expression levels or prevalence across different tumor samples (e.g., some tumor samples might have slightly smaller or lighter dots for specific markers). Overall, the separation of marker profiles between the two conditions is robust.

Biological Interpretation

Fibroblasts play a critical role in tissue homeostasis in normal conditions, maintaining extracellular matrix (ECM) integrity and secreting growth factors. In the tumor microenvironment (TME), fibroblasts undergo activation, transforming into Cancer-Associated Fibroblasts (CAFs), which actively promote tumor growth, invasion, metastasis, angiogenesis, and immune suppression. The differential surfaceome expression observed here provides insight into this phenotypic transition.

Markers Enriched in Adjacent Normal Fibroblasts

These markers represent proteins involved in normal fibroblast function and tissue homeostasis. Their reduced expression in tumor-associated fibroblasts could signify a loss of normal tissue-maintaining functions.

• PLPP3 (Phospholipid Phosphatase 3): Involved in sphingolipid metabolism and signal transduction, influencing cell growth and differentiation. It typically plays a role in suppressing cell proliferation and inflammation. Its downregulation in CAFs might contribute to the pro-proliferative TME. GeneCards link
• SCARA5 (Scavenger Receptor Class A Member 5): A cell surface receptor involved in endocytosis and adhesion. It can mediate the clearance of apoptotic cells and interact with collagen. Its loss in CAFs could impair normal ECM turnover and cell clearance processes. GeneCards link
• GPNMB (Glycoprotein NMB): Involved in cell adhesion, migration, and anti-inflammatory responses. Expressed in various cell types and implicated in tissue repair and immune regulation. Its altered expression can affect TME immune modulation.
• CD34: A transmembrane glycoprotein expressed on hematopoietic stem and progenitor cells, but also on some stromal progenitor cells and endothelial cells. In fibroblasts, it can mark a subset of stromal progenitors or quiescent fibroblasts. Its loss often correlates with CAF activation.
• PTPRA (Protein Tyrosine Phosphatase Receptor Type A): A receptor-type protein tyrosine phosphatase that regulates cell adhesion and growth factor signaling. It can dephosphorylate src family kinases, influencing cell proliferation and survival. UniProt link

Markers Enriched in Tumor Fibroblasts (Cancer-Associated Fibroblasts, CAFs)

These markers are characteristic of activated fibroblasts and often contribute to the pro-tumorigenic properties of the TME. They represent potential targets for cancer therapy.

FAP (Fibroblast Activation Protein):

• Signaling Pathways: Primarily involved in ECM remodeling through its dipeptidyl peptidase and endopeptidase activity, cleaving various ECM proteins and growth factors. It also modulates Wnt signaling.
• Role in TME: A classical marker of activated CAFs. FAP+ CAFs promote tumor growth, invasion, angiogenesis, and immunosuppression by modifying the ECM, releasing pro-tumorigenic cytokines, and interacting with immune cells.
• Therapeutic Target Potential: High. FAP is highly restricted in expression in normal adult tissues but upregulated in many cancers, making it an attractive target.
• Therapeutic Agents: FAP-targeted therapies are under active development, including FAP-specific antibodies (e.g., sibrotuzumab, although clinical trial data have been mixed), FAP-targeted CAR-T cells, and FAP-targeting small molecule inhibitors or radioligands. PubMed search: FAP colorectal cancer therapy

PDGFRB (Platelet-Derived Growth Factor Receptor Beta):

• Signaling Pathways: A receptor tyrosine kinase activated by PDGF ligands, leading to downstream signaling cascades involving PI3K/Akt and MAPK pathways, which promote cell proliferation, survival, migration, and angiogenesis.
• Role in TME: Drives CAF activation, proliferation, and recruitment. PDGFRB signaling is crucial for desmoplasia (dense fibrous stroma) formation and pericyte recruitment, essential for angiogenesis.
• Therapeutic Target Potential: Moderate to high. Targeting PDGFRB can reduce stromal support for tumors.
• Therapeutic Agents: Tyrosine kinase inhibitors (TKIs) like Imatinib, Sunitinib, and Sorafenib, which inhibit PDGFRB, are used in various cancers. Clinical trials are exploring their efficacy in combination with chemotherapy or immunotherapy for solid tumors by targeting the TME. GeneCards link

CD44:

• Signaling Pathways: A ubiquitous cell surface adhesion molecule and receptor for hyaluronic acid (HA). Involved in cell-cell and cell-matrix interactions, cell migration, proliferation, and survival. It can interact with various growth factors and proteases.
• Role in TME: CD44 is often associated with cancer stem cells and contributes to tumor initiation, progression, metastasis, and drug resistance. In CAFs, CD44 can mediate cell adhesion to ECM, facilitate migration, and regulate inflammatory responses.
• Therapeutic Target Potential: High, particularly due to its role in cancer stemness and metastasis.
• Therapeutic Agents: Anti-CD44 antibodies and small molecule inhibitors are being investigated. PubMed search: CD44 cancer therapy

ITGAV (Integrin Subunit Alpha V) & ITGA1/ITGA5 (Integrin Subunit Alpha 1/5):

• Signaling Pathways: Integrins are heterodimeric cell surface receptors that mediate cell-ECM and cell-cell adhesion, transducing mechanical and biochemical signals that regulate cell proliferation, survival, migration, and differentiation. ITGAV often pairs with beta subunits (e.g., ITGB1, ITGB3, ITGB5, ITGB6) to form receptors for various ECM proteins like fibronectin, vitronectin, and collagen.
• Role in TME: CAFs heavily rely on integrin signaling for adhesion, migration within the stiff tumor ECM, and for promoting angiogenesis and cancer cell invasion. ITGAV-containing integrins are particularly implicated in TGF-β activation, a key pathway for CAF activation and fibrosis.
• Therapeutic Target Potential: Moderate to high. Disrupting integrin signaling can impair tumor progression and metastasis.
• Therapeutic Agents: Integrin-targeting antibodies (e.g., Etrolizumab targeting α4β7 for IBD) and RGD-mimetic small molecules are under investigation in oncology. UniProt link for ITGAV

CDH11 (Cadherin-11):

• Signaling Pathways: A classical cadherin involved in Ca2+-dependent homophilic cell-cell adhesion. It mediates cell aggregation and sorting, often associated with mesenchymal cell types.
• Role in TME: In CAFs, CDH11 can promote cell migration and invasion, contributing to tumor progression. It facilitates interactions between tumor cells and fibroblasts, and between fibroblasts themselves, aiding in stromal stiffening and remodeling.
• Therapeutic Target Potential: Emerging. Its role in tumor progression and fibrosis makes it an interesting candidate.
• Therapeutic Agents: CDH11-blocking antibodies are in preclinical development for fibrotic diseases and cancer. GeneCards link

ANTXR1 (Anthrax Toxin Receptor 1, also known as TEM8):

• Signaling Pathways: Functions as a receptor for anthrax toxin, but also plays physiological roles in angiogenesis and cell adhesion by binding to collagen type IV and laminin.
• Role in TME: ANTXR1 is upregulated in tumor endothelial cells and fibroblasts and contributes to tumor angiogenesis and ECM remodeling. It is implicated in promoting tumor cell migration and survival.
• Therapeutic Target Potential: High, due to its upregulation in the tumor vasculature and stroma.
• Therapeutic Agents: ANTXR1-targeting antibodies are being developed to inhibit tumor angiogenesis and growth. UniProt link

ENG (Endoglin, CD105):

• Signaling Pathways: A co-receptor for TGF-β, primarily expressed on endothelial cells but also on activated fibroblasts. It modulates TGF-β signaling, affecting proliferation, migration, and angiogenesis.
• Role in TME: As a TGF-β co-receptor, ENG plays a critical role in promoting tumor angiogenesis and fibrosis. In CAFs, its expression enhances TGF-β-mediated activation and ECM production.
• Therapeutic Target Potential: High, especially for anti-angiogenic and anti-fibrotic strategies.
• Therapeutic Agents: TRC105 (anti-endoglin antibody) has been investigated in clinical trials for various solid tumors. GeneCards link

PTK7 (Protein Tyrosine Kinase 7):

• Signaling Pathways: A catalytically inactive receptor tyrosine kinase that acts as a pseudokinase, primarily involved in Wnt signaling (both canonical and non-canonical) and cell migration.
• Role in TME: PTK7 is overexpressed in various cancers and promotes cell proliferation, migration, invasion, and stemness. In CAFs, it could regulate Wnt-mediated signaling pathways that contribute to CAF activation and TME remodeling.
• Therapeutic Target Potential: High, due to its widespread overexpression in cancer and its role in critical oncogenic pathways.
• Therapeutic Agents: Antibody-drug conjugates (ADCs) targeting PTK7 (e.g., PF-06647080) are under clinical development. UniProt link

CD276 (B7-H3):

• Signaling Pathways: An immune checkpoint molecule belonging to the B7 family. It primarily acts as an immune suppressive molecule, inhibiting T cell activation and proliferation, but it can also promote tumor cell growth and metastasis.
• Role in TME: In CAFs, CD276 expression contributes to the immunosuppressive TME, protecting tumor cells from immune surveillance. It can directly inhibit T cell effector functions and promote a pro-tumorigenic cytokine milieu.
• Therapeutic Target Potential: Very high. CD276 is broadly expressed across many cancers and is a promising target for immunotherapy.
• Therapeutic Agents: Anti-CD276 antibodies (e.g., Enoblituzumab) and CD276-targeted CAR-T cells are in clinical trials. PubMed search: CD276 B7H3 cancer immunotherapy

PLAUR (Plasminogen Activator, Urokinase Receptor):

• Signaling Pathways: Binds urokinase-type plasminogen activator (uPA), localizing plasminogen activation to the cell surface, leading to localized proteolysis of ECM proteins. This facilitates cell migration and tissue remodeling.
• Role in TME: Upregulated in many cancers and CAFs, PLAUR promotes tumor invasion and metastasis by facilitating ECM degradation. It can also enhance cell adhesion and growth factor signaling.
• Therapeutic Target Potential: Moderate, as it is involved in multiple aspects of tumor progression.
• Therapeutic Agents: Inhibitors targeting the uPA/uPAR system are being investigated as anti-cancer agents. GeneCards link

OSMR (Oncostatin M Receptor):

• Signaling Pathways: A receptor for Oncostatin M (OSM), part of the IL-6 cytokine family, activating JAK/STAT, MAPK, and PI3K pathways. It is involved in inflammation, fibrosis, and cell growth.
• Role in TME: In CAFs, OSMR signaling can promote chronic inflammation, fibrosis, and ECM remodeling, creating a permissive environment for tumor growth and metastasis. It can also induce expression of pro-tumorigenic cytokines.
• Therapeutic Target Potential: Emerging, particularly in cancers where chronic inflammation and fibrosis are prominent.
• Therapeutic Agents: Agents targeting OSM/OSMR signaling are in development for inflammatory and fibrotic diseases, with potential for oncology applications. UniProt link

ADAM9 (ADAM Metallopeptidase Domain 9):

• Signaling Pathways: A member of the ADAM (A Disintegrin And Metalloprotease) family, involved in shedding of cell surface proteins (e.g., growth factors, receptors), cell-cell fusion, and ECM remodeling.
• Role in TME: Overexpressed in CAFs, ADAM9 contributes to tumor progression by shedding growth factors, enabling their activation, and by mediating cell-cell and cell-ECM interactions crucial for invasion and metastasis.
• Therapeutic Target Potential: Emerging. Inhibiting ADAMs can disrupt multiple pro-tumorigenic processes.
• Therapeutic Agents: ADAM inhibitors are being explored in cancer therapy, often in combination with other agents. GeneCards link

F3 (Tissue Factor):

• Signaling Pathways: The primary initiator of the extrinsic coagulation cascade, binding Factor VII/VIIa. Beyond coagulation, F3 signaling activates protease-activated receptors (PARs), influencing cell proliferation, migration, angiogenesis, and inflammation.
• Role in TME: Tumor cells and CAFs often overexpress F3, contributing to a procoagulant state in cancer patients and directly promoting tumor growth, angiogenesis, and metastasis through PAR signaling.
• Therapeutic Target Potential: High, due to its dual roles in coagulation and direct tumor progression.
• Therapeutic Agents: Targeting F3 and its downstream pathways is an active area of research for anti-cancer and anti-thrombotic therapies in cancer. UniProt link

Clinical or Translational Implications

The identification of these distinct surfaceome markers on CAFs in colorectal carcinoma has several important clinical and translational implications:

1. Diagnostic and Prognostic Biomarkers: Markers like FAP, PDGFRB, CD44, and CD276 could serve as diagnostic or prognostic markers for colorectal carcinoma. Elevated expression of these CAF-associated markers might correlate with tumor stage, invasiveness, or patient outcomes. Immunohistochemical staining or liquid biopsy (e.g., circulating CAF-derived exosomes) for these markers could provide valuable clinical information.
2. Therapeutic Targets for Stroma-Targeted Therapies: The marked overexpression of these surface proteins in tumor fibroblasts, coupled with their relatively low expression in adjacent normal tissue, makes them attractive targets for developing stroma-targeted therapies.

• FAP stands out as a highly promising target, with various therapeutic modalities including small molecule inhibitors, antibodies, and CAR-T cells currently under investigation.
• CD276 (B7-H3) represents an exciting immune checkpoint target, and targeting it in CAFs could help overcome the immunosuppressive TME, potentially enhancing the efficacy of existing immunotherapies.
• PDGFRB, Integrins (ITGAV/A1/A5), ENG, and PTK7 also offer avenues for inhibiting critical CAF functions such as proliferation, migration, angiogenesis, and ECM remodeling.

3. Combination Therapies: Given the complex and heterogeneous nature of the TME, single-agent therapies targeting CAFs may have limited efficacy. Combining CAF-targeted therapies (e.g., FAP inhibitors) with conventional chemotherapy, radiation, or immune checkpoint inhibitors could be a powerful strategy to overcome tumor resistance and improve patient responses in colorectal cancer.
4. Experimental Validation: These identified markers provide a strong basis for further experimental validation.

• In vitro studies: Using primary human CAFs derived from colorectal cancer patients to confirm functional roles of these markers (e.g., adhesion, migration, cytokine secretion) and evaluate the efficacy of targeted agents.
• In vivo studies: Employing patient-derived xenograft (PDX) models or genetically engineered mouse models (GEMMs) of colorectal cancer to assess the therapeutic potential of targeting these CAF surface markers, evaluating tumor growth, metastasis, and changes in the TME.
• Clinical trials: Based on promising preclinical data, designing early-phase clinical trials to test the safety and preliminary efficacy of novel agents targeting these CAF markers in colorectal cancer patients.

18. T cell CD4+ Condition-Specific Surfaceome Markers in Colorectal Carcinoma

[Analysis Visualization Results]...

Analysis Overview

This analysis identifies condition-specific surfaceome markers for CD4+ T cells in Colorectal Carcinoma (CRC) by comparing gene expression in Tumor and adjacent normal (Adj_normal) tissues using single-cell RNA sequencing data. The dot plot visualizes the mean expression level and the fraction of cells expressing each marker across various samples within the two conditions. The objective is to highlight surface markers that are differentially expressed, offering insights into the immunological landscape of CRC and potential therapeutic targets.

Visual Summary

The dot plot displays the expression of 19 surfaceome markers in CD4+ T cells across multiple individual samples, separated into "Adj_normal" and "Tumor" conditions.

• Overall Pattern: CD4+ T cells in the "Tumor" microenvironment generally exhibit a higher mean expression (darker red color) and a greater fraction of expressing cells (larger dot size) for most identified markers compared to CD4+ T cells from "Adj_normal" tissues. This indicates a more activated or transcriptionally active state of CD4+ T cells within the tumor.
• Tumor-Enriched Markers: Nearly all displayed markers show prominent upregulation in tumor samples. Notably, immune checkpoint molecules such as CTLA4 and TIGIT are almost exclusively and strongly expressed in CD4+ T cells from tumor samples, with high prevalence across many tumor specimens.
• Costimulatory Markers: Costimulatory receptors like TNFRSF4 (OX40), TNFRSF18 (GITR), and ICOS are also markedly upregulated in tumor-associated CD4+ T cells. Their expression suggests an ongoing immune response or an attempt at activation within the tumor microenvironment, despite the presence of inhibitory signals.
• Adhesion and Signaling Molecules: Markers such as CD2, CD44, CD53, ICAM3, and CD63, involved in cell adhesion, signal transduction, and T cell activation, show generally higher expression and prevalence in tumor samples.
• Other Upregulated Markers: CD74, IL2RG, EMP3, LY6E, HLA-F, BST2, CD164, and TNFRSF1B are also consistently more expressed in CD4+ T cells from tumor tissue compared to adjacent normal tissue.
• Adj_normal Expression: CD4+ T cells in "Adj_normal" samples generally exhibit lower expression levels and frequencies for most markers, though some samples show moderate expression of a subset of markers (e.g., CD2, CD74, IL2RG, CD44, CD53, EMP3, LY6E), albeit typically less pronounced than in tumor samples. This indicates a relatively quiescent state or a different functional profile compared to their tumor-infiltrating counterparts.

Biological Interpretation

CD4+ T cells play a critical and complex role in the Colorectal Carcinoma tumor microenvironment (TME), acting as both promoters and inhibitors of anti-tumor immunity depending on their subtype and activation state. The observed marker expression profile suggests a highly dynamic and often dysfunctional state of CD4+ T cells within CRC.

Markers and their Biological Roles in Tumor-Associated CD4+ T cells:

1. Immune Checkpoints (Inhibitory):

• CTLA4: Cytotoxic T-lymphocyte associated protein 4. This co-inhibitory receptor is upregulated on activated T cells, including CD4+ T cells, and competitively binds to CD80/CD86 on antigen-presenting cells (APCs), dampening T cell activation and proliferation. Its strong expression in tumor CD4+ T cells suggests a mechanism of immune suppression within the CRC TME, contributing to tumor immune escape [1].
• TIGIT: T cell immunoreceptor with Ig and ITIM domains. TIGIT is another inhibitory receptor expressed on various immune cells, including T cells. It binds to poliovirus receptor (PVR/CD155) and nectin-2 (CD112) on APCs and tumor cells, inhibiting T cell activation and proliferation, promoting T cell exhaustion, and enhancing Treg suppressive function. Its high expression in tumor CD4+ T cells suggests a role in maintaining an immunosuppressive TME in CRC [2].

2. Costimulatory Receptors (Activating/Modulatory):

• TNFRSF4 (OX40): Tumor necrosis factor receptor superfamily member 4. An activating receptor primarily expressed on activated CD4+ T cells. OX40 engagement promotes T cell survival, proliferation, and cytokine production (e.g., IL-2, IFN-$\gamma$), enhancing anti-tumor immunity [3]. Its upregulation in tumor-infiltrating CD4+ T cells indicates T cell activation, which might be counteracted by inhibitory signals or represents a pro-survival mechanism.
• TNFRSF18 (GITR): Glucocorticoid-induced TNFR-related protein. Another costimulatory receptor expressed on activated T cells and regulatory T cells (Tregs). GITR signaling enhances the proliferation and effector function of CD4+ and CD8+ T cells, while reducing the suppressive activity of Tregs [4]. Its presence suggests an attempt by CD4+ T cells to maintain an activated state or respond to environmental cues, potentially within an otherwise suppressive context.
• ICOS: Inducible T-cell co-stimulator. A CD28 superfamily costimulatory receptor expressed on activated T cells, particularly follicular helper T cells (Tfh) and Th17 cells. ICOS signaling promotes T cell proliferation, survival, and cytokine production (e.g., IL-10, IL-21, IFN-$\gamma$), playing diverse roles in immunity and inflammation. In cancer, ICOS can support both anti-tumor and pro-tumor responses depending on the T cell subset and context [5]. Its expression indicates active T cell signaling in CRC.

3. Adhesion and Other Signaling Molecules:

• CD2: T-cell surface glycoprotein involved in T cell activation, adhesion, and signaling. It binds to CD58 on APCs and other cells. Upregulation may signify increased cell-cell interactions within the TME.
• CD44: Cell-surface glycoprotein involved in cell adhesion, migration, and lymphocyte activation. It is a receptor for hyaluronic acid and is often associated with cancer cell stemness and metastasis. Its expression on CD4+ T cells can regulate their trafficking and function within the TME [6].
• CD74: MHC class II invariant chain. Beyond its role in antigen presentation, CD74 can act as a receptor for macrophage migration inhibitory factor (MIF), a cytokine implicated in inflammation, angiogenesis, and tumor growth. CD74-MIF interaction can activate signaling pathways that promote cell survival and proliferation [7].
• IL2RG: Interleukin-2 receptor subunit gamma (common gamma chain). A crucial component of multiple cytokine receptors (e.g., IL-2, IL-4, IL-7, IL-9, IL-15, IL-21 receptors), vital for lymphocyte development, proliferation, and survival. Its upregulation indicates active cytokine signaling pathways critical for T cell function in the TME.
• EMP3: Epithelial membrane protein 3. A myelin protein that has been observed to be dysregulated in various cancers. Its specific role in T cells in the TME is less characterized but could be involved in cell-cell interactions or modulating cell properties.
• LY6E: Lymphocyte antigen 6 complex locus E. A GPI-anchored protein involved in T cell activation and differentiation. It's often upregulated in various cancers and can contribute to immune evasion or T cell exhaustion.
• ICAM3: Intercellular adhesion molecule 3. A cell surface glycoprotein involved in lymphocyte adhesion and T cell activation through binding to LFA-1. Its expression facilitates T cell interactions with APCs and other cells.
• HLA-F: A non-classical MHC class I molecule. While MHC class I molecules are typically involved in presenting antigens to CD8+ T cells, non-classical MHC molecules like HLA-F have diverse immunomodulatory roles, including interactions with NK cells and T cells, influencing immune responses in the TME.
• BST2 (CD317): Bone marrow stromal antigen 2 (tetherin). An interferon-inducible protein involved in innate and adaptive immunity, including antiviral defense. Its role in tumor T cells is under investigation, but it can influence immune cell activation and cytokine production.
• CD164: Sialomucin core protein. Involved in cell adhesion, growth regulation, and hematopoiesis. Its role in T cells in cancer can be multifaceted, influencing cell migration and interactions.
• TNFRSF1B (TNFR2): Tumor necrosis factor receptor superfamily member 1B. Receptor for TNF-$\alpha$. TNFR2 signaling can promote cell survival, proliferation, and differentiation, particularly important for regulatory T cells and myeloid cells, potentially contributing to an immunosuppressive environment or chronic inflammation [8].
• CD53, CD63: Tetraspanins. These transmembrane proteins organize molecular complexes on the cell surface, influencing cell adhesion, migration, proliferation, and signal transduction. Their upregulation in tumor-infiltrating T cells suggests increased cellular activity and interaction dynamics.

In the context of Colorectal Carcinoma, the simultaneous upregulation of both costimulatory (OX40, GITR, ICOS) and coinhibitory (CTLA4, TIGIT) receptors on CD4+ T cells suggests a complex state where T cells are activated but also heavily regulated and potentially driven towards exhaustion or a suppressive phenotype by the persistent antigenic stimulation and immunosuppressive TME. This can lead to a state of chronic inflammation that fuels tumor progression, or an ineffective anti-tumor immune response.

Clinical or Translational Implications

The identified surfaceome markers on CD4+ T cells in CRC hold significant clinical and translational potential as therapeutic targets, biomarkers, and indicators for guiding immunotherapy strategies.

1. Immunotherapy Targets:

• CTLA4 and TIGIT: The prominent expression of these immune checkpoint inhibitors on tumor-infiltrating CD4+ T cells makes them prime targets for immune checkpoint blockade (ICB) therapies.
• CTLA4: Ipilimumab (Yervoy) is an FDA-approved anti-CTLA4 antibody used in melanoma and other cancers. While anti-CTLA4 monotherapy has had limited success in CRC, combinations with anti-PD-1/PD-L1 are being explored for specific CRC subsets (e.g., MSI-H/dMMR CRC) [9].
• TIGIT: Several anti-TIGIT antibodies (e.g., tiragolumab, domvanalimab) are in clinical trials, often in combination with anti-PD-1/PD-L1 therapies, showing promising results in various solid tumors, including CRC. Targeting TIGIT aims to unleash anti-tumor immunity by blocking its inhibitory signals [10].
• TNFRSF4 (OX40), TNFRSF18 (GITR), and ICOS: These costimulatory receptors represent targets for agonistic antibodies designed to enhance anti-tumor T cell responses.
• OX40 agonists: Antibodies that activate OX40 (e.g., MEDI6469, MOXR0916) are in clinical development to boost T cell proliferation, survival, and effector function, thereby promoting a more robust anti-tumor immune response.
• GITR agonists: Agonistic antibodies targeting GITR (e.g., TRX518, BMS-986178) aim to enhance effector T cell activity and counteract Treg-mediated suppression, making the TME more conducive to anti-tumor immunity.
• ICOS agonists: Activating ICOS (e.g., JTX-2011) can promote the activity of effector T cells and certain helper T cell subsets, potentially enhancing anti-tumor immunity, particularly in combination settings.

2. Biomarkers: The expression levels and patterns of these markers on CD4+ T cells could serve as prognostic or predictive biomarkers.

• High expression of inhibitory receptors (CTLA4, TIGIT) might indicate a more immunosuppressive TME and potentially predict response to corresponding ICB therapies.
• The balance between costimulatory and inhibitory markers could inform patient stratification for targeted immunotherapies. For instance, high OX40/GITR expression in the presence of low CTLA4/TIGIT might predict a better response to therapies aiming to unleash existing T cell activity.

3. Understanding T cell Plasticity: The co-expression of multiple costimulatory and inhibitory receptors highlights the complex plasticity and adaptation of CD4+ T cells within the CRC TME. Further research into how these markers dictate specific CD4+ T cell functional states (e.g., Th1, Th17, Treg, exhausted) could reveal novel therapeutic avenues to reprogram these cells for effective anti-tumor immunity.
4. Novel Targets: While less explored as direct targets for immunotherapy, markers like CD74 (MIF receptor), CD44 (involved in adhesion/migration), and IL2RG (key for cytokine signaling) could be investigated for indirect therapeutic modulation or as components of combination therapies to optimize T cell function and trafficking in the CRC TME.

These findings underscore the rationale for precision immunotherapy approaches in CRC, where understanding the specific phenotypic state of immune cells, like CD4+ T cells, within the tumor is crucial for designing effective treatment strategies.

---

References:

1. CTLA4: UniProt entry for CTLA4: https://www.uniprot.org/uniprot/P16410
2. TIGIT: PubMed search for "TIGIT cancer immunotherapy": https://pubmed.ncbi.nlm.nih.gov/?term=TIGIT+cancer+immunotherapy
3. TNFRSF4 (OX40): UniProt entry for TNFRSF4: https://www.uniprot.org/uniprot/P43489
4. TNFRSF18 (GITR): UniProt entry for TNFRSF18: https://www.uniprot.org/uniprot/Q9Y5Q2
5. ICOS: UniProt entry for ICOS: https://www.uniprot.org/uniprot/Q9Y6W8
6. CD44: GeneCards entry for CD44: https://www.genecards.org/cgi-bin/carddisp.pl?gene=CD44
7. CD74: PubMed search for "CD74 MIF cancer": https://pubmed.ncbi.nlm.nih.gov/?term=CD74+MIF+cancer
8. TNFRSF1B (TNFR2): GeneCards entry for TNFRSF1B: https://www.genecards.org/cgi-bin/carddisp.pl?gene=TNFRSF1B
9. Ipilimumab in CRC: PubMed search for "ipilimumab colorectal cancer": https://pubmed.ncbi.nlm.nih.gov/?term=ipilimumab+colorectal+cancer
10. TIGIT in CRC: PubMed search for "TIGIT colorectal cancer immunotherapy": https://pubmed.ncbi.nlm.nih.gov/?term=TIGIT+colorectal+cancer+immunotherapy

19. Differential Expression of Cell Cycle Genes in Colorectal Carcinoma Epithelial Cells

[Analysis Visualization Results]...

Analysis Overview

This analysis investigates the expression patterns of a predefined set of cell cycle pathway genes within Intestinal Epithelial cells, comparing their expression in colorectal carcinoma (Tumor) tissue against adjacent normal (Adj_normal) tissue. The goal is to identify genes with statistically significant expression differences between these two conditions, providing insights into the proliferative state and dysregulation characteristic of cancer. The expression is quantified as the "expressing cell fraction (sample)," which represents the proportion of Intestinal Epithelial cells within each sample that express a given gene.

Visual Summary

The visualization displays box plots for 24 distinct cell cycle pathway genes. Each plot compares the "expressing cell fraction (sample)" in Intestinal Epithelial cells between the 'Adj_normal' and 'Tumor' conditions.

Key observations from the plots are:

• Consistent Upregulation in Tumor: Across all 24 genes presented, the expressing cell fraction is markedly and consistently higher in the 'Tumor' condition compared to the 'Adj_normal' condition. The median expression fraction (represented by the central line within the box) for these genes is substantially elevated in tumor samples.
• High Statistical Significance: All displayed genes show extremely low p-values (ranging from approximately 1e-21 to 1e-27), indicating a highly statistically significant difference in expression fraction between the tumor and adjacent normal tissues for every gene. This suggests that the observed differences are highly unlikely to be due to random chance.
• Magnitude of Difference: For many genes, such as CCND1, MCM7, CDK7, MYC, and CDC25B, the median expressing cell fraction in tumor samples is several-fold higher than in adjacent normal samples, with considerable spread (interquartile range) suggesting this is a robust finding across multiple tumor samples. This large difference indicates a widespread and strong activation of cell cycle machinery in the tumor Intestinal Epithelial cells.

Biological Interpretation

The observed upregulation of these cell cycle genes in Intestinal Epithelial cells from colorectal tumor tissues compared to adjacent normal tissues provides strong biological insights consistent with the hallmarks of cancer, particularly uncontrolled proliferation.

The identified genes are central to various stages of the cell cycle:

• Cell Cycle Progression Drivers: Genes like CCND1 (Cyclin D1), CDK4, CDK7, CDK2, and CDC25B are crucial regulators that drive cells through the G1/S and G2/M phases of the cell cycle. Their overexpression leads to accelerated cell division and loss of cell cycle control, a hallmark of cancer. GeneCards: CCND1, GeneCards: CDK4
• DNA Replication Machinery: The Minichromosome Maintenance (MCM) complex proteins, including MCM2, MCM3, MCM4, and MCM7, are helicases essential for initiating DNA replication. Their high expression signifies active DNA synthesis and rapid cell proliferation, which is a characteristic feature of cancerous growth. GeneCards: MCM7
• Oncogenic Transcription Factors: MYC is a well-known oncogene that functions as a transcription factor, regulating genes involved in cell growth, proliferation, and metabolism. Its consistent upregulation in tumor Intestinal Epithelial cells is a common driver in colorectal carcinoma progression. GeneCards: MYC
• Mitotic Checkpoint and Chromosome Segregation: Genes such as BUB3, MAD2L2, ANAPC7, ANAPC10, ANAPC13, CDC20, and SMC3 are involved in the spindle assembly checkpoint (SAC) and anaphase-promoting complex/cyclosome (APC/C), which ensure proper chromosome segregation during mitosis. Their elevated expression can reflect increased mitotic activity or a stressed and dysregulated mitotic process typical of aneuploid tumor cells. GeneCards: BUB3
• DNA Damage Response and Repair: PRKDC (DNA-PKcs) is a key component of the non-homologous end joining (NHEJ) pathway for DNA double-strand break repair. Its upregulation may indicate increased genomic instability and active DNA repair mechanisms operating in rapidly dividing tumor cells to survive DNA damage. GeneCards: PRKDC
• Chromatin Remodeling: HDAC2 (Histone Deacetylase 2) is involved in chromatin structure and gene expression regulation. Dysregulation of HDACs is common in cancer and contributes to altered gene expression programs that favor proliferation. GeneCards: HDAC2

The consistent upregulation of this broad panel of cell cycle genes in the 'Intestinal Epithelial cell' population, which is identified as the tumor-origin cell type in the context of Colon tissue and Colorectal Carcinoma, directly supports the biological understanding of cancer as a disease of uncontrolled cell growth and division. This indicates that tumor Intestinal Epithelial cells are undergoing rapid and dysregulated proliferation compared to their normal counterparts.

Clinical or Translational Implications

The robust upregulation of these cell cycle genes in colorectal carcinoma Intestinal Epithelial cells carries several significant clinical and translational implications:

• Diagnostic and Prognostic Biomarkers: The identified genes, particularly those showing the largest fold-changes and highest statistical significance (e.g., CCND1, MCM7, MYC), could serve as powerful diagnostic or prognostic biomarkers for colorectal cancer. Their detection or quantification in biopsies or liquid biopsies could aid in early diagnosis, assessment of tumor aggressiveness, or prediction of disease recurrence.
• Therapeutic Targets: Many of these upregulated cell cycle regulators and components are established or emerging therapeutic targets in oncology. For instance:
• CDK inhibitors: Targeting CDKs (like CDK4) is a successful strategy in various cancers. The high expression of CDKs in colorectal epithelial tumor cells suggests their potential as effective therapeutic targets in this context.
• MYC inhibitors: Given MYC's central role in driving proliferation, strategies to inhibit MYC activity are actively being explored in cancer therapy.
• HDAC inhibitors: These drugs are already used in some cancers and could be investigated for colorectal carcinoma, particularly given the elevated HDAC2 expression.
• Targeting DNA replication (MCM proteins) or mitotic machinery (BUB, MAD2L2, ANAPC components) could be alternative avenues to arrest tumor growth.

This analysis pinpoints specific cell cycle components that are highly active in the tumor cells, suggesting a vulnerability that could be exploited by targeted therapies. PubMed search: Cell cycle inhibitors colorectal cancer

• Monitoring Treatment Response: Changes in the expression of these genes could be monitored during treatment to assess the efficacy of therapies, especially those designed to inhibit cell proliferation or induce cell cycle arrest. A decrease in the expression of these markers post-treatment could indicate a positive response.

20. Gene Ontology (GSA) Analysis for Intestinal Epithelial Cells in Colorectal Carcinoma

[Analysis Visualization Results]...

Analysis Overview

This analysis presents Gene Ontology (GSA) enrichment results for Intestinal Epithelial cells, comparing different conditions: 'Adj_normal' versus 'others', 'Diploid' versus 'others', and 'Tumor' versus 'others'. The enrichment is based on up-regulated differentially expressed genes (DEGs) for each comparison. The findings highlight significant biological processes and pathways characteristic of Intestinal Epithelial cells under these distinct conditions within the context of Colorectal Carcinoma. The 'Intestinal Epithelial cell' was identified as the resolved tumor-origin cell type in this dataset.

Visual Summary

The provided bar plots illustrate the top enriched Gene Ontology terms based on up-regulated DEGs for Intestinal Epithelial cells across three comparisons:

1. GSA for Intestinal Epithelial cell: Adj_normal_vs_others (Based on up-regulated DEGs)

• This plot shows pathways enriched in Intestinal Epithelial cells from adjacent normal tissue. Prominently enriched terms include "Non-alcoholic fatty liver disease," "Diabetic cardiomyopathy," "Oxidative phosphorylation," "Thermogenesis," "Parkinson Disease," "Alzheimer Disease," "Fatty acid degradation," "Prion disease," "PPAR signaling pathway," and "Pathways of neurodegeneration." These terms are primarily related to metabolic processes (e.g., oxidative phosphorylation, fatty acid degradation) and a spectrum of complex diseases, including neurodegenerative conditions.

2. GSA for Intestinal Epithelial cell: Diploid_vs_others (Based on up-regulated DEGs)

• This plot highlights terms up-regulated in diploid Intestinal Epithelial cells. The most highly enriched terms are "Ribosome" and "Coronavirus disease," both showing very strong statistical significance (high -log(p-val) and -log(q-val)).

3. GSA for Intestinal Epithelial cell: Tumor_vs_others (Based on up-regulated DEGs)

• This plot details pathways up-regulated in Intestinal Epithelial cells specifically from tumor tissue. A wide array of terms are enriched, including "Amyotrophic lateral sclerosis," "Endocytosis," "Ubiquitin mediated proteolysis," "Protein processing in endoplasmic reticulum," "Spliceosome," "RNA transport," "Cell Cycle," "Huntington disease," "Pathways of neurodegeneration," "Alzheimer disease," and notably "Colorectal cancer" itself. Other significant terms relate to viral infections (e.g., "Epstein-Barr virus infection," "Human T-cell leukemia virus 1 infection," "Hepatitis B"), apoptosis, and various signaling pathways (e.g., mTOR, p53, TNF, AMPK, MAPK).

Biological Interpretation

The Gene Ontology analysis provides valuable insights into the functional state of Intestinal Epithelial cells in the context of colorectal carcinoma:

• Adjacent Normal Epithelium (Adj_normal_vs_others): The enrichment of terms like "Oxidative phosphorylation" and "Fatty acid degradation" suggests a baseline metabolic activity geared towards energy production in healthy or adjacent normal intestinal epithelial cells. The recurring presence of neurodegenerative disease terms (e.g., Parkinson, Alzheimer, Prion diseases, Amyotrophic lateral sclerosis, Pathways of neurodegeneration) in this and other comparisons is noteworthy. While these conditions are not directly related to colon biology, the underlying cellular mechanisms (e.g., protein misfolding, mitochondrial dysfunction, oxidative stress, inflammation, and cellular clearance pathways) are shared across various disease contexts, including cancer. This could indicate a general cellular stress response or altered homeostasis in the seemingly "normal" adjacent tissue, possibly as a field effect of the tumor presence, or simply an overlap of gene sets involved in general cellular maintenance or stress.
• Diploid Cells (Diploid_vs_others): The robust enrichment of the "Ribosome" term in diploid Intestinal Epithelial cells strongly indicates active protein synthesis. This is a fundamental characteristic of healthy, proliferating cells required for normal tissue maintenance and function. The "Coronavirus disease" term might reflect a shared gene signature with general cellular stress or immune response pathways activated even in otherwise healthy cells.
• Tumor Epithelium (Tumor_vs_others): This comparison reveals a dramatic shift in the biological landscape of Intestinal Epithelial cells within the tumor microenvironment:
• Oncogenic Pathways: The direct enrichment of "Colorectal cancer" validates the tumor identity. Terms like "Cell Cycle" and "Apoptosis" are critical hallmarks of cancer, with dysregulated cell cycle progression leading to uncontrolled proliferation and altered apoptotic pathways contributing to tumor survival and resistance to therapy. PubMed search: cell cycle apoptosis colorectal cancer
• Protein Homeostasis and Stress Response: Pathways such as "Ubiquitin mediated proteolysis," "Protein processing in endoplasmic reticulum," "Spliceosome," "RNA transport," and "Lysosome" are highly active. This suggests that tumor cells are under immense proteotoxic stress due to high metabolic demands and rapid proliferation, necessitating enhanced protein quality control, processing, and degradation machinery. Aberrant splicing is also a known feature in cancer. PubMed search: protein quality control cancer
• Infection and Immunity-Related Pathways: The enrichment of terms related to various viral infections (e.g., "Epstein-Barr virus infection," "Human T-cell leukemia virus 1 infection," "Hepatitis B," "Human papillomavirus infection," "Viral carcinogenesis") and bacterial infections (e.g., "Salmonella infection," "Shigellosis") is intriguing. While some viruses are known oncogenes, these terms might also indicate common host response pathways engaged by chronic inflammation or immune evasion strategies employed by tumor cells, which share molecular signatures with infectious processes. The colon microbiome is known to influence colorectal cancer development. PubMed search: microbiome colorectal cancer
• Metabolic and Signaling Reprogramming: The presence of various signaling pathways like "mTOR signaling pathway," "p53 signaling pathway," "TNF signaling pathway," "AMPK signaling pathway," and "MAPK signaling pathway" indicates significant reprogramming of cell growth, metabolism, survival, and inflammatory responses—all crucial for tumor progression.
• Neurodegenerative Disease Overlap: The continued high enrichment of neurodegenerative disease terms in tumor cells may reflect a severe general cellular stress, protein aggregation, or mitochondrial dysfunction that is broadly shared with these conditions, rather than a direct neurological pathology. For example, protein misfolding and aggregation can lead to proteotoxicity, which cancer cells must actively manage.

Clinical or Translational Implications

This GSA analysis in Intestinal Epithelial cells provides potential avenues for understanding colorectal carcinoma pathogenesis and identifying therapeutic targets:

• Targeting Oncogenic Pathways: The strong enrichment of "Cell Cycle" pathways directly highlights their importance in tumor proliferation. Inhibitors targeting specific cell cycle checkpoints (e.g., CDK4/6 inhibitors) could be relevant therapeutic strategies for these epithelial cells. PubMed search: cell cycle inhibitors colorectal cancer
• Protein Homeostasis as Vulnerability: The pronounced up-regulation of pathways related to protein processing, degradation, and RNA metabolism suggests that tumor cells are heavily reliant on these systems to cope with high protein synthesis and proteotoxic stress. Targeting components of the ubiquitin-proteasome system or ER stress response could selectively inhibit tumor cell survival.
• Inflammation and Infection-Associated Signatures: The presence of various infection-related GO terms points to the intricate interplay between inflammation, the local immune microenvironment, and potential microbial factors in colorectal cancer. Further investigation into specific pathogen signatures or chronic inflammatory pathways could reveal novel therapeutic targets or prevention strategies, particularly those modulating the gut microbiome.
• Metabolic Reprogramming: While "Oxidative phosphorylation" is enriched in adjacent normal cells, the overall metabolic landscape is likely shifted in tumor cells (implied by signaling pathways like AMPK and mTOR). Understanding these shifts could lead to metabolic interventions that selectively starve cancer cells.
• Relevance of Neurodegenerative Overlap: The recurring enrichment of neurodegenerative disease-related pathways, while not directly indicative of neurological disease in the colon, underscores shared fundamental cellular stress mechanisms. Investigating the specific genes contributing to these terms might reveal common vulnerabilities in protein handling and cellular stress response in tumor cells that could be therapeutically exploited.

21. Gene Set Enrichment Analysis (GSEA) of Cell-Type-Specific Pathways in Colorectal Carcinoma

[Analysis Visualization Results]...

Analysis Overview

This analysis presents Gene Set Enrichment Analysis (GSEA) results visualized as a dot plot. The GSEA was performed for various cell populations (celltype_minor) identified in single-cell RNA-seq data from Colon tissue, comparing specific conditions against a reference. Specifically, for each cell type, gene expression profiles in the "Tumor" condition were compared against those in the "Adj_normal" condition (and vice versa) for the same cell type. For Intestinal Epithelial cells, comparisons were further stratified by ploidy status (Diploid and Aneuploid) within the Tumor condition against their respective counterparts in Adj_normal tissue.

Each dot in the plot represents a specific pathway (y-axis) enriched in a particular cell population and condition (x-axis).

• Dot Color: Indicates the Normalized Enrichment Score (NES). Red signifies positive enrichment (pathway upregulated), and blue signifies negative enrichment (pathway downregulated) in the tested condition relative to the reference. The color map used is RdBu_r, which is suitable for visualizing both positive and negative enrichment.
• Dot Size: Represents the statistical significance (-log(P) value), with larger dots indicating more significant enrichment (smaller p-values).

The results highlight key biological pathways that are differentially active across various cell types in the tumor microenvironment of colorectal carcinoma compared to adjacent normal tissue.

Visual Summary

The dot plot reveals a complex landscape of pathway enrichment across different cell types and conditions. A prominent pattern is the strong positive enrichment (large red dots) of numerous cancer-associated pathways in Intestinal Epithelial cells from the Tumor condition, particularly in the aneuploid population. These include "Pathways in cancer," "Colorectal cancer," "DNA replication," "Wnt signaling pathway," and "HIF-1 signaling pathway." Conversely, these pathways generally show negative enrichment (blue dots) or absence in Intestinal Epithelial cells from the Adj_normal condition.

Immune cells (Macrophages, T cells, Dendritic cells) within the Tumor microenvironment exhibit altered immune signaling pathways such as "Chemokine signaling pathway," "Cytokine-cytokine receptor interaction," and "NF-kappa B signaling pathway," often with positive enrichment. Stromal cells like Fibroblasts and Endothelial cells in the Tumor condition show strong positive enrichment for pathways related to extracellular matrix (ECM) remodeling ("ECM-receptor interaction"), cell adhesion ("Focal adhesion"), and angiogenesis ("HIF-1 signaling pathway"). Metabolic pathways like "Glutathione metabolism" and "Oxidative phosphorylation" are also notably enriched in malignant epithelial cells.

Biological Interpretation

Tumor-Origin Intestinal Epithelial Cells

The analysis of Intestinal Epithelial cells (IECs), identified as the tumor-origin cell type, provides direct insights into the malignancy.

• Aneuploid IECs in Tumor: These cells display the most robust and significant positive enrichment for core cancer hallmarks. Pathways such as "Pathways in cancer" [1], "Colorectal cancer" [2], "DNA replication," "Mismatch repair" [3], "Homologous recombination," "Wnt signaling pathway" [4], "HIF-1 signaling pathway" [5], and "MAPK signaling pathway" are highly upregulated. This indicates active proliferation, genomic instability, altered cell signaling crucial for tumor growth, adaptation to hypoxia, and a high protein synthesis rate ("Ribosome" pathway). Elevated "Glutathione metabolism" and "Pentose phosphate pathway" suggest increased antioxidant defense and nucleotide synthesis, supporting rapid cell division. "Oxidative phosphorylation" enrichment might indicate a metabolic shift that, alongside aerobic glycolysis (Warburg effect, not directly listed but related), supports biomass production in tumor cells.
• Diploid IECs in Tumor: While generally less pronounced than in aneuploid cells, diploid IECs within the tumor also show positive enrichment for many cancer-associated pathways. This suggests that even diploid epithelial cells in the tumor microenvironment may be influenced by oncogenic signaling or represent a pre-malignant or early transforming state.
• Comparison to Adj_normal IECs: Adjacent normal IECs typically show negative enrichment for these oncogenic pathways, confirming their tumor-specific activation.

Tumor Microenvironment Immune Cells

The GSEA results highlight significant alterations in immune cell functions within the tumor microenvironment (TME).

• Macrophages: Tumor-associated macrophages (TAMs) show strong positive enrichment for "Chemokine signaling pathway" [6], "Cytokine-cytokine receptor interaction," "NF-kappa B signaling pathway," "Phagosome," and "Toll-like receptor signaling pathway." This profile is consistent with an activated, often pro-tumorigenic M2-like phenotype, contributing to immune suppression, angiogenesis, and matrix remodeling in CRC.
• T cells (CD4+ and CD8+): Both CD4+ and CD8+ T cells in the Tumor show enrichment for "Cytokine-cytokine receptor interaction," "Chemokine signaling pathway," and "NF-kappa B signaling pathway." This suggests that T cells are actively sensing and responding to the TME, which can lead to various outcomes, including anti-tumor immunity or exhaustion. "Th17 cell differentiation" enrichment is observed in Tumor CD4+ T cells, indicating a potential role of this T cell subset in CRC progression.
• Dendritic Cells: Tumor dendritic cells show positive enrichment for "Antigen processing and presentation," suggesting their involvement in immune surveillance, although their function might be modulated by the tumor.

Tumor Microenvironment Stromal Cells

Stromal cells play critical roles in shaping the tumor microenvironment and supporting tumor growth.

• Fibroblasts: Tumor fibroblasts (Cancer-Associated Fibroblasts, CAFs) exhibit robust enrichment for "ECM-receptor interaction" [7], "Focal adhesion," "MAPK signaling pathway," "Wnt signaling pathway," and "HIF-1 signaling pathway." This indicates their active role in extensive ECM remodeling, promoting tumor cell invasion, and contributing to angiogenic and proliferative signaling.
• Endothelial Cells: Tumor endothelial cells show positive enrichment for "HIF-1 signaling pathway" [5] and "MAPK signaling pathway," which are central to angiogenesis (new blood vessel formation) that fuels tumor growth. "Vascular smooth muscle contraction" is also enriched, possibly reflecting altered vascular tone or remodeling in tumor vessels.

Metabolic Reprogramming and Genomic Instability

Beyond specific cell types, the pervasive enrichment of metabolic pathways (e.g., "Glutathione metabolism," "Pentose phosphate pathway," "Oxidative phosphorylation") in tumor cells underscores the significant metabolic reprogramming required to sustain rapid proliferation and survival in the harsh TME. Similarly, the strong upregulation of "DNA replication," "Mismatch repair," and "Homologous recombination" pathways in aneuploid IECs highlights the heightened proliferative activity and ongoing DNA damage and repair processes characteristic of malignant cells.

Clinical or Translational Implications

The distinct pathway enrichments observed across cell types in the colorectal carcinoma microenvironment offer several potential clinical and translational implications:

• Therapeutic Targets: Pathways consistently activated in aneuploid tumor IECs, such as Wnt, HIF-1, and MAPK signaling, represent established therapeutic targets for CRC. The specific enrichment patterns observed here could guide the development of targeted therapies or combination strategies to inhibit multiple pathways simultaneously.
• Biomarkers: Upregulated pathways in specific tumor-associated cell types (e.g., ECM-receptor interaction in fibroblasts, specific cytokine interactions in macrophages) could yield novel biomarkers for disease progression, prognosis, or response to therapy.
• Immune Checkpoint Modulation: Understanding the altered immune signaling in T cells, macrophages, and dendritic cells can inform strategies for immune checkpoint blockade or other immunotherapies. Targeting pro-tumorigenic macrophage pathways or enhancing anti-tumor T cell responses could be effective.
• Metabolic Intervention: The observed metabolic reprogramming, particularly the reliance on specific pathways for antioxidant defense (Glutathione metabolism) or nucleotide synthesis (Pentose phosphate pathway), suggests potential for metabolic interventions to starve tumor cells or reduce their resilience.
• Ploidy-Specific Strategies: The clear differentiation in pathway activity between diploid and aneuploid tumor IECs emphasizes the distinct biological characteristics of these cell populations. Future therapies could potentially be tailored to target highly aneuploid, more aggressive tumor cells, or to prevent the progression of diploid cells towards aneuploidy.

References

1. Pathways in cancer: A broad category encompassing various oncogenic signaling cascades. For general context, see: PubMed search for "pathways in cancer"
2. Colorectal cancer: Specifically curated pathways relevant to CRC pathophysiology. For general context, see: PubMed search for "colorectal cancer signaling pathways"
3. DNA mismatch repair: Crucial for maintaining genomic integrity, often deficient in certain CRC subtypes (e.g., MSI-H). See: UniProt entry for MSH2 (a key mismatch repair protein)
4. Wnt signaling pathway: A critical developmental pathway frequently aberrantly activated in CRC. See: GeneCards entry for WNT pathway
5. HIF-1 signaling pathway: Hypoxia-inducible factor 1 (HIF-1) plays a key role in tumor adaptation to low oxygen conditions and angiogenesis. See: GeneCards entry for HIF1A
6. Chemokine signaling pathway: Critical for immune cell recruitment and migration within the tumor microenvironment. See: PubMed search for "chemokine signaling cancer immunity"
7. ECM-receptor interaction: Essential for cell adhesion, migration, and tissue architecture, often dysregulated in cancer metastasis. See: PubMed search for "ECM receptor interaction cancer"

22. Discussion

The single-cell analysis of colorectal carcinoma (CRC) reveals a profoundly reprogrammed tumor microenvironment, distinct from adjacent normal tissue, with significant implications for disease progression and therapeutic strategies.

At the core of the malignancy, Intestinal Epithelial cells are unequivocally identified as the tumor-origin population, exhibiting widespread aneuploidy and extensive genomic instability. This is evidenced by recurrent copy number amplifications of key oncogenes, including *EGFR* (7p11.2), *MYC* (8q24.21), and *ERBB2* (17q12), which are well-established drivers of CRC pathogenesis. Furthermore, these malignant epithelial cells show a dramatic and consistent upregulation of a broad spectrum of cell cycle progression genes, DNA replication machinery, and oncogenic transcription factors like *MYC*, underscoring their uncontrolled proliferative capacity. Gene Set Enrichment Analysis (GSEA) and Gene Ontology (GSA) further corroborate this, demonstrating robust activation of fundamental cancer pathways such as Wnt, HIF-1, and MAPK signaling, alongside a strong reliance on protein homeostasis and metabolic reprogramming pathways (e.g., glutathione metabolism, pentose phosphate pathway) to sustain their rapid growth.

The immune landscape within the CRC tumor microenvironment is markedly altered towards an immunosuppressive state. A statistically significant increase in the proportion of regulatory T cells (Tregs) and exhausted CD8+ T cells is observed, which are critical mediators of immune evasion, dampening effective anti-tumor responses. Conversely, CD8 Memory T cells and naive CD4+ T cells are significantly reduced. Macrophages, highly plastic immune cells, undergo a critical polarization shift. While an initial overview might suggest M1 dominance in some tumor samples, the more granular analysis of macrophage subsets reveals a significant increase in pro-tumorigenic M2C and M2B populations, accompanied by a decrease in M2A and M2D subsets. This shift indicates a re-education of macrophages towards phenotypes that promote immune suppression, angiogenesis, and tumor growth, which is a common, but complex, feature of tumor-associated macrophages (TAMs) in CRC. The tumor-infiltrating CD4+ T cells also show a striking upregulation of both co-inhibitory receptors (CTLA4, TIGIT) and co-stimulatory receptors (OX40, GITR, ICOS), reflecting a state of chronic activation that is simultaneously constrained by inhibitory signals, leading to T cell dysfunction.

The stromal compartment is also extensively remodeled, with fibroblasts transforming into Cancer-Associated Fibroblasts (CAFs). These CAFs exhibit distinct surfaceome markers such as FAP, PDGFRB, CD44, and the immune checkpoint molecule CD276 (B7-H3). These activated fibroblasts contribute to extracellular matrix (ECM) remodeling, promoting tumor invasion, angiogenesis, and establishing an immunosuppressive niche. The identified cell-cell interaction networks provide further depth, highlighting crucial communication axes such as the ubiquitous CXCL12-CXCR4 and PPIA-CD147 pathways that facilitate tumor growth, invasion, and immune evasion. Particularly notable is the extensive involvement of TGF-β signaling, including the Integrin αvβ6-TGFB1 activation axis between malignant epithelial cells and macrophages, a potent driver of immunosuppression and fibrosis. The strong PD-1/PD-L1 interactions between tumor cells and T cells further confirm immune checkpoint activation.

In summary, this analysis delineates a highly dynamic and hostile microenvironment in colorectal carcinoma, where malignant epithelial cells actively proliferate and remodel their surroundings, while subverting immune responses through complex cell-cell interactions and phenotypic shifts in both immune and stromal compartments. These integrated findings provide a comprehensive single-cell atlas of CRC progression and pinpoint numerous critical pathways and cell surface molecules as potential targets for advanced therapeutic strategies.

Hypotheses:

1. Aneuploid Intestinal Epithelial cells possess a more aggressive, proliferative, and invasive phenotype compared to diploid tumor epithelial cells, driving CRC progression.
2. The increased presence of regulatory T cells (Tregs) and exhausted CD8+ T cells in the CRC tumor microenvironment is a primary mechanism of immune evasion, directly correlating with a diminished effective anti-tumor immune response.
3. The specific enrichment of M2C and M2B macrophage subsets in tumors indicates their distinct pro-tumorigenic and immunosuppressive roles, contributing to angiogenesis, immune evasion, and metastasis.
4. The upregulation of specific surface markers like FAP, PDGFRB, and CD276 on Cancer-Associated Fibroblasts (CAFs) directly mediates their pro-tumorigenic functions, including extracellular matrix (ECM) remodeling and active immune suppression, critical for CRC progression.
5. Inhibiting critical cell-cell interaction pathways like CXCL12-CXCR4, PPIA-CD147, or the Integrin αvβ6-TGFB1 axis can disrupt tumor-promoting communication, overcome immune evasion, and suppress tumor growth in colorectal carcinoma.

Potential therapeutic targets:

1. EGFR (Epidermal Growth Factor Receptor): EGFR is recurrently amplified (7p11.2) in tumor-origin Intestinal Epithelial cells, and its activation by ligands (HBEGF, AREG, TGFA) drives cell proliferation, survival, and metastasis. EGFR signaling is a key oncogenic pathway in CRC. Evidence: CNV heatmap (recurrent amplification of EGFR locus 7p11.2), Intestinal Epithelial cell surfaceome markers (implied by high HBEGF/AREG/TGFA ligands binding EGFR), Cell-cell interaction analysis (HBEGF/AREG/TGFA-EGFR interactions), GSEA shows MAPK pathway enrichment. Anti-EGFR therapies are established for CRC. Validation: Test anti-EGFR therapies (e.g., Cetuximab, Panitumumab) in CRC patient-derived organoids or xenografts with EGFR amplification. Correlate in situ EGFR amplification and expression with clinical response to anti-EGFR agents in patient cohorts.
2. PD-1 / PD-L1 (Programmed Death-1 / Programmed Death-Ligand 1): PD-L1 (CD274) - PD-1 (PDCD1) interactions are highly prominent and strong in tumor samples, involving both diploid and aneuploid Intestinal Epithelial cells interacting with CD8+ T cells. This critical immune checkpoint axis inhibits T cell activity, allowing tumor cells to evade anti-tumor immunity. Evidence: T cell CD4+ surfaceome markers (CTLA4, TIGIT, also inhibitory), Cell-cell interaction analysis (CD274-PDCD1 interactions), GSEA shows NF-kappa B signaling pathway in immune cells. Validation: Evaluate the efficacy of anti-PD-1/PD-L1 antibodies (e.g., Pembrolizumab, Nivolumab, Atezolizumab) in CRC models (e.g., syngeneic mouse models, humanized mouse models) alone and in combination with other agents. Correlate PD-L1 expression on tumor cells and immune cells, and T cell exhaustion markers in patient tumors with response to immune checkpoint blockade (ICB).
3. TIGIT (T cell immunoreceptor with Ig and ITIM domains): TIGIT is highly and almost exclusively expressed on tumor-associated CD4+ T cells. Its binding to PVR/CD155 on APCs and tumor cells inhibits T cell activation, promotes T cell exhaustion, and enhances Treg suppressive function, thereby contributing to an immunosuppressive tumor microenvironment. Evidence: T cell CD4+ condition-specific surfaceome markers show strong and exclusive upregulation of TIGIT in tumor samples. Validation: Test anti-TIGIT antibodies (e.g., tiragolumab) in combination with anti-PD-1/PD-L1 therapies in CRC models. Evaluate changes in T cell function and anti-tumor immunity. Assess TIGIT expression on tumor-infiltrating lymphocytes in patient samples.
4. TGF-β Signaling Pathway (e.g., TGFB1-TGFBR1/2/3): There are very extensive and strong interactions involving TGFB1 with its receptors across a wide range of tumor cell types (Intestinal Epithelial cells, Macrophages, T cells, Fibroblasts). The Integrin αvβ6-TGFB1 activation axis is also strongly upregulated, creating a potent feed-forward loop. TGF-β promotes epithelial-to-mesenchymal transition (EMT), angiogenesis, and immunosuppression. Evidence: Cell-cell interaction analysis (TGFB1-TGFBR, Integrin_avb6_complex-TGFB1 interactions), GSEA shows enrichment of Wnt signaling and MAPK signaling in tumor cells and stromal cells. Validation: Utilize TGFBR1 kinase inhibitors (e.g., Galunisertib) or TGF-β neutralizing antibodies in CRC models to assess effects on tumor growth, metastasis, and immune microenvironment modulation (e.g., Treg reduction, effector T cell activation). Investigate co-targeting integrin αvβ6 with TGF-β inhibition.
5. FAP (Fibroblast Activation Protein): FAP is a classical marker of activated Cancer-Associated Fibroblasts (CAFs), highly restricted in expression in normal adult tissues but extensively expressed in tumor fibroblasts. FAP+ CAFs promote tumor growth, invasion, angiogenesis, and immunosuppression by modifying the ECM and releasing pro-tumorigenic cytokines. Evidence: Fibroblast condition-specific surfaceome markers show strong upregulation of FAP in tumor fibroblasts. GSEA shows ECM-receptor interaction and Focal adhesion pathway enrichment in fibroblasts. Validation: Evaluate FAP-targeted therapies (e.g., FAP-specific antibodies, FAP-targeted CAR-T cells, small molecule inhibitors) in CRC patient-derived xenografts or syngeneic models. Analyze effects on stromal remodeling, immune cell infiltration, and tumor growth.
6. CXCR4 (CXC Chemokine Receptor Type 4): The CXCL12-CXCR4 axis is consistently strong and widespread in tumor samples, involving diverse cell pairs including Intestinal Epithelial cells, Endothelial cells, Fibroblasts, Macrophages, and T cells. This axis promotes tumor cell growth, invasion, angiogenesis, and recruits immunosuppressive cells to the tumor microenvironment. Evidence: Condition-specific cell-cell interaction patterns show robust CXCL12-CXCR4 interactions in tumor samples. Validation: Test CXCR4 antagonists (e.g., Plerixafor) in CRC models to inhibit metastasis and potentially enhance the efficacy of chemotherapy and immunotherapy by modulating immune cell trafficking. Assess impact on tumor cell proliferation and invasion in vitro.
7. CD47 (Cluster of Differentiation 47): CD47 acts as a 'don't eat me' signal to macrophages by binding to SIRPα. Its overexpression on malignant Intestinal Epithelial cells in tumor samples allows cancer cells to evade phagocytic clearance by macrophages, contributing to immune escape. Evidence: Intestinal Epithelial cell surfaceome markers show upregulation of CD47 in tumor samples. Macrophage condition-specific surfaceome markers show SIRPα expression on macrophages. Validation: Evaluate anti-CD47 antibodies (e.g., Magrolimab) in CRC models (e.g., humanized mouse models) to promote macrophage-mediated phagocytosis of tumor cells. Assess phagocytic activity of tumor-associated macrophages ex vivo and its impact on tumor growth in vivo.

Follow-up validation ideas:

1. Functional validation of aneuploid Intestinal Epithelial cell aggressiveness: Isolate aneuploid and diploid Intestinal Epithelial cells from patient tumors (e.g., using flow cytometry) and compare their proliferative capacity, invasive potential, and metastatic fitness in in vitro (organoid models) and in vivo (patient-derived xenograft) assays.
2. Treg and T cell exhaustion functional assays: Perform ex vivo functional assays on sorted T cell subsets from tumor and adjacent normal tissues (e.g., proliferation, cytokine production upon TCR stimulation). Use flow cytometry or multiplex immunofluorescence to quantify Treg/effector T cell ratios and expression of exhaustion markers (PD-1, CTLA-4, TIGIT) in tumor biopsies and correlate with clinical outcomes.
3. Macrophage polarization and functional assays: Isolate tumor-associated macrophages (TAMs) and adjacent normal macrophages and conduct in vitro polarization assays (e.g., cytokine production upon M1/M2 stimuli), phagocytosis assays, and co-culture experiments with CRC tumor cells to assess their pro-tumorigenic or anti-tumor effects. Immunostaining of tumor biopsies for M2C/M2B markers could validate their spatial distribution and abundance.
4. CAF targeting and TME modulation: Use FAP-CreERT2 mouse models or specific CAF surface marker knockdown (e.g., CRISPR) in primary human CAFs to evaluate the impact on ECM remodeling, immune cell infiltration, and tumor growth in co-culture or in vivo models. Spatial transcriptomics or multiplex imaging could map CAF marker expression relative to immune cells.
5. CCI perturbation studies: Use blocking antibodies or small molecule inhibitors against key ligand-receptor pairs (e.g., CXCR4, CD147, Integrin αvβ6, TGFBR1) in in vitro co-culture systems (tumor cells + immune/stromal cells) and in vivo CRC models to assess changes in cell proliferation, migration, invasion, angiogenesis, and immune cell function/infiltration.
6. CNV validation in patient cohorts: Validate recurrent CNV amplifications (EGFR, MYC, ERBB2) identified in single cells using FISH (Fluorescence In Situ Hybridization) or ddPCR (digital droplet PCR) on larger cohorts of CRC patient samples to correlate with clinical outcomes and therapeutic response.

Limitations:

This report is based on single-cell RNA sequencing data, which, while offering unparalleled cellular resolution, inherently loses spatial context that may be critical for certain cell-cell interactions and microenvironmental structures. The inference of colorectal carcinoma as the primary disease, though strongly supported by comprehensive metadata and biological findings, remains provisional without direct clinical diagnosis. Cell-cell interaction analyses are inferred from ligand-receptor expression and require experimental validation to confirm functional significance. While a macrophage population bar plot (Section 9) suggested an M1 dominance in some tumor samples, the more granular and statistically significant box plots of macrophage subsets (Section 10) revealed a consistent increase in M2C and M2B populations, indicating the complex and sometimes nuanced nature of single-cell classifications and the importance of multiple analytical perspectives. The 'Diploid Tumor' epithelial cells, though not explicitly aneuploid, still exhibit altered gene expression and interactions within the tumor microenvironment, necessitating careful interpretation of their specific role. Furthermore, observed differences in cell proportions and gene expression reflect associations rather than proven causal relationships, requiring further functional validation. The significant patient-to-patient heterogeneity observed across various analyses underscores that findings might not be universally applicable and warrant validation in larger, diverse cohorts.

23. Query List

1. Show and save UMAPs for condition, sample, celltype_major, celltype_minor, ploidy_dec, and celltype_subset in two columns.
2. Show major cell type scores on UMAP and save the result.
3. Show and save a marker expression dot plot for celltype_subset. SET target_cell = None and var_group_rotation = 45. Leave all other arguments at their default values.
4. Select Intestinal Epithelial cells, show a CNV heatmap grouped by sample together with a summary of regions with significantly amplified copy numbers, and save the results.
5. Show and save UMAPs of CNV patterns colored by celltype_major, celltype_minor, ploidy_dec, condition, and sample in two columns.
6. Show and save a population bar plot of minor cell types.
7. Show and save a population bar plot of T cell subsets.
8. Show and save box plots of T cell subset populations with statistically significant differences between conditions, if any. Choose ncols based on the total number of panels.
9. Show and save a population bar plot of macrophage subsets.
10. Show and save box plots of macrophage subset populations with statistically significant differences between conditions, if any. Choose ncols based on the total number of panels.
11. Select Intestinal Epithelial cells, show their ploidy populations as a bar plot, and save the result.
12. Show and save cell-cell interaction patterns involving Intestinal Epithelial cells, fibroblasts, macrophages, T cells, and other relevant cell types. Select at most 80 cell-cell interactions per group.
13. Find cell-cell interactions involving Intestinal Epithelial cells, major immune and stromal cells that differ significantly between conditions, show them as a dot plot, and save the result. Set max_n_items_per_group to 60. For each interaction identified under each condition, using the provided dataset context, describe the associated signaling pathways and mechanisms, its potential as a therapeutic target, and relevant therapeutic agents.
14. Find cell-cell interactions containing immune checkpoint and cell cycle pathway genes and involving Intestinal Epithelial cells, major immune and stromal cells that differ significantly between conditions, show them as a dot plot, and save the result. Set max_n_items_per_group to 60. For each interaction identified under each condition, using the provided dataset context, describe the associated signaling pathways and mechanisms, its potential as a therapeutic target, and relevant therapeutic agents.
15. Show marker expressions for Intestinal Epithelial cells in a dot plot, and save the result. Use only surfaceome markers, with at most 60 markers per condition. For the markers identified under each condition, distinguish between established therapeutic targets and less well-characterized markers with potential as therapeutic targets. For each marker, using the provided dataset context, describe the associated signaling pathways and mechanisms, relevant therapeutic agents, and supporting evidence.
16. Show marker expressions for Macrophage in a dot plot, and save the result. Use only surfaceome markers, with at most 40 markers per condition. For each marker identified under each condition, using the provided dataset context, describe the associated signaling pathways, the role of the corresponding cell type in the tumor microenvironment, the marker’s potential as a therapeutic target, relevant therapeutic agents, and other pertinent information.
17. Show marker expressions for Fibroblast in a dot plot, and save the result. Use only surfaceome markers, with at most 40 markers per condition. For each marker identified under each condition, using the provided dataset context, describe the associated signaling pathways, the role of the corresponding cell type in the tumor microenvironment, the marker’s potential as a therapeutic target, relevant therapeutic agents, and other pertinent information.
18. Show marker expressions for T cell CD4+ in a dot plot, and save the result. Use only surfaceome markers, with at most 40 markers per condition. For each marker identified under each condition, using the provided dataset context, describe the associated signaling pathways, the role of the corresponding cell type in the tumor microenvironment, the marker’s potential as a therapeutic target, relevant therapeutic agents, and other pertinent information.
19. Among cell cycle pathway genes, select those with statistically significant expression differences between conditions in Intestinal Epithelial cells, show box plots, and save the result. Set max_n_items_to_plot to 24 and choose ncols based on the total number of panels for an overall width-to-height ratio of approximately 2:3.
20. Show and save Gene Ontology (GSA) analysis results for Intestinal Epithelial cells as a bar plot.
21. Show Gene Set Enrichment Analysis results as a dot plot, and save it. Set the color map to RdBu_r, n_pws_to_show to 120, and target_cells to None.